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Healthcare stakeholders need access to the evidence about the adverse events 
(AEs) of health interventions to make informed clinical decisions. This dissertation 
addresses research gaps in the collection and reporting of AEs in randomized controlled 
trials (RCTs).  
Methods 
We examined sources about RCTs of gabapentin for neuropathic pain and 
quetiapine for bipolar depression (“eligible” RCTs). We identified public sources (e.g., 
journal articles) and non-public sources (e.g., clinical study reports) available by March 
2015 (gabapentin) and January 2015 (quetiapine). We extracted data about non-
systematic (e.g., unsolicited by investigators) and systematic (e.g., collected using 
questionnaires) AEs, including “serious” AEs (defined by the Food and Drug 
Administration). We compared reporting of non-systematic (Aim 1) and systematic (Aim 
2) AEs in public and non-public sources. We assessed whether AEs were “meta-
analyzable” (i.e., we could calculate between-group effects) and whether systematic AE 
outcomes were “fully-defined” (i.e., specified all five elements of an outcome). In Aim 3, 
we extracted and compared “selection criteria” (i.e., reported methods for selecting 
which non-systematic AEs to report) and assessed the impact of selection criteria on 




We identified 21 gabapentin RCTs and 7 quetiapine RCTs. In Aim 1, the majority of non-
systematic AEs were reported only in non-public sources for gabapentin (341/419 
[81%]) and quetiapine (436/471 [93%]). Most serious non-systematic AEs were reported 
only in non-public sources: 56/72 (78%) and 39/46 (85%) for gabapentin and quetiapine. 
Gabapentin RCTs did not report any systematic AEs, so Aim 2 is based on only 
quetiapine RCTs. About half (90/159; 57%) of all results in public sources were both 
associated with defined outcomes and meta-analyzable, compared with nearly all 
(610/636; 96%) results in non-public sources. In Aim 3, all selection criteria we identified 
were based on a numerical threshold for reporting (e.g., ≥5%). Choice of selection 
criteria had a large impact on both the AEs reported in individual RCTs and meta-
analysis results.  
Conclusions 
Poor reporting of non-systematic and systematic AEs has consequences for healthcare 
stakeholders. Without open access to non-public sources, healthcare decisions are 
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Adverse events (AEs) are an important consideration in patient-centered 
research, as indicated by the priorities of the National Academy of Medicine (1), the 
Patient-Centered Outcomes Research Institute (PCORI)  (2), and the United States 
Department of Health and Human Services (3). AEs are also important to regulators, 
who determine whether the potential benefits of an intervention outweigh the 
potential AEs for products being considered for indication approval (4). Regulatory 
approval is typically based on the results of randomized controlled trials (RCTs) (4). This 
dissertation is focused on the collection and reporting of AEs in RCTs.  
Methods for collecting and classifying adverse events 
During an RCT, AEs can be collected using two main methods. “Non-systematic 
AEs” are either reported by patients without being solicited by trial investigators or 
solicited using broad, open-ended questions such as, “have you noticed any changes 
since your last visit?” (5, 6). Non-systematic AEs are collected as free-text that describes 
participant experiences (5, 6). Free-text responses are consolidated and coded to 
facilitate analysis (7). For example, two participants might experience similar AEs, but 
use different wording to describe them (e.g., head pain vs. headache). To facilitate 
analysis, these two different descriptions would be coded as the same AE (8-10). 
Although the goal of coding non-systematic AEs for analysis is to standardize data within 
and across trials, this can prove challenging; even experienced coders may code the 




lead to inconsistency both within and across trials, which may complicate comparison of 
the safety of different interventions (7). 
When AEs are suspected of being related to the intervention, they might be 
collected systematically (“systematic AEs”). Systematic AEs are collected and recorded 
in the same manner for each participant at pre-specified intervals using methods of 
ascertainment that are related to specific AEs (5, 6). Some examples of systematic 
collection methods are laboratory tests (e.g., blood glucose), vital signs (e.g., blood 
pressure), questionnaires (e.g., the Young Mania Rating Scale), and checklists. 
Systematic AEs can be described using a framework that includes five elements of an 
outcome: (1) domain (e.g., mania); (2) specific measurement (e.g., Young Mania Rating 
Scale); (3) metric (e.g., a participant’s change in Young Mania Rating Scale from 
baseline); (4) method of data aggregation for analysis (e.g., mean Young Mania Rating 
Scale score, proportion of participants reaching a particular threshold); and (5) time-
point at which the outcome was assessed (11, 12). An outcome would be considered 
“fully-defined” if all five elements of the outcome were clearly specified. For example, 
“mania symptoms as assessed by the mean change from baseline to eight weeks using 
the Young Mania Rating Scale” would be considered fully-defined; “mania symptoms 
assessed using the Young Mania Rating Scale” would not be considered fully-defined 
because it is missing the metric, method of aggregation, and time-point. According to 
the FDA, “[p]otential problems that may be suspected because of preclinical data or 




It is important to distinguish between these two methods of AE data collection. 
Evidence suggests that when investigators use different methods to collect AEs (i.e., 
systematic vs. non-systematic), different proportions of patients may report 
experiencing AEs (14-18). For example, one RCT randomized participants to different 
methods of AE data collection and found that participants who were asked to use a 
checklist reported about 20 times more AEs than participants who were asked an open-
ended question (15). Other evidence suggests that the proportion of patients reporting 
sexual side effects from selective serotonin reuptake inhibitors (SSRIs, a class of anti-
depressants) ranges from 2% to 73%, and that this variation arises largely from whether 
AEs were collected using non-systematic or systematic methods (18). The difference in 
the proportion of participants reporting AEs makes it difficult to both synthesize 
information from multiple trials about the same intervention and condition and 
compare different interventions for the same condition.  
Both non-systematic and systematic AEs can be classified as “serious.” Serious 
AEs are categorized as such by trial investigators, typically based on definitions 
determined by regulatory agencies. The FDA defines serious AEs as “death, a life-
threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substantial disruption of the 
ability to conduct normal life functions, or a congenital anomaly/birth defect” (19, 20). 




Consistency of adverse event collection across trials  
During the process of designing an RCT, investigators must select which 
outcomes they are interested in collecting, analyzing, and reporting. During this process, 
investigators must determine not only which outcome domains (e.g., depression, mania) 
to collect, but also how they will collect data about each outcome domain. When there 
are multiple options, selecting an instrument to use for data collection can prove 
challenging. For example, there are hundreds of different scales that measure 
psychiatric symptoms (22). When there are this many different ways to assess each 
outcome domain, trial investigators may understandably choose to collect different 
fully-defined outcomes even when they identify the same outcome domains as 
important for collection. Inconsistent collection of outcomes across RCTs complicates 
synthesizing data from multiple RCTs about the same intervention and condition or 
comparing the relative effectiveness and safety of different interventions for the same 
condition.  
To increase consistency of outcomes across RCTs, there has been increased 
research related to developing “core outcome sets,” which are “an agreed minimum set 
of outcomes” to be collected during studies about the same condition (23, 24). 
Established methods for developing core outcomes sets vary widely and may include the 
Delphi Technique, surveys, semi-structured discussion, and unstructured group 
discussion, among others (25). The stakeholders involved in developing core outcome 




non-clinical research experts (e.g., statisticians, epidemiologists), regulatory agencies, 
policy-makers, journal editors, and others (25). The Core Outcome Measures in 
Effectiveness Trials (COMET) Initiative seeks to standardize methods for developing core 
outcome sets and compile a searchable database of completed and ongoing core 
outcome sets (23). 
Current core outcome sets are typically focused on outcomes to be collected in 
studies related to a particular condition (24) to facilitate comparison of different 
interventions for the same condition. It may be inappropriate, however, to collect the 
same AEs for all interventions for a particular condition; different types of interventions 
may have different expected AEs. For example, bipolar depression can be treated using 
both pharmaceutical interventions (e.g., quetiapine) and behavioral interventions (e.g., 
cognitive behavioral therapy). These two types of interventions are likely to have very 
different expected AEs, so it may be inappropriate to collect data about the same AEs. 
Therefore, it may be better to develop core outcome sets of AEs that are specific to 
types of interventions (e.g., drug class). For example, it would be important to be able to 
compare the relative weight gain that participants experience on different types of 
atypical anti-psychotics. In some cases, it might even be appropriate to examine the 
same AEs across different conditions. For example, quetiapine is approved for use in 
patients with schizophrenia, as well as bipolar disorder; the FDA approved label for 




The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) has developed a suggested core outcome set for studies that are assessing 
chronic pain conditions (27). This core outcome set makes recommendations for several 
effectiveness outcome domains that should be collected, as well as which measurement 
tools should be used to collect each of these effectiveness outcome domains. However, 
the core outcome set does not make specific recommendations related to the collection 
of AEs. Instead, they recommend collecting “symptoms and adverse events” (27). 
Although the report states that systematic methods of collecting AEs are often more 
sensitive and provide more informative than non-systematic methods, it provides little 
guidance as to which AEs should be collected systematically or what measurement tools 
should be used. Because both effectiveness and AE outcomes are important and AE 
outcomes may be underdeveloped in current core outcome sets, it might be 
appropriate to have two separate core outcome sets for effectiveness and AE outcomes. 
Potential sources of data about adverse events 
After data are collected during RCTs, these data must be analyzed and reported. 
We have developed a theoretical framework to describe the different sources of RCT 
data about AEs and how these different sources of evidence may contribute to 
systematic reviews and meta-analyses, which combine data from multiple studies to 
calculate a summary effect estimate (Figure 1-1). When an RCT is conducted, data are 
recorded on case report forms. These data are then entered into a database, making up 




abstracts, journal articles, clinical trial registries such as ClinicalTrials.gov, and, when the 
RCT is conducted by a pharmaceutical company for regulatory approval, CSRs and CSR-
Synopses. CSRs and sometimes IPD are submitted to regulatory agencies, such as the 
FDA, for drug approval. The FDA reviews the submitted data and creates its own 
reports. The FDA also works with the company to create and approve a label for the 
medication.  
Systematic reviewers can then use a mix of sources (abstracts, journal articles, 
clinical trial registries, FDA reviews, CSRs, CSR-Synopses, and IPD) to perform meta-
analyses. We have classified these sources as either public (i.e., abstracts, journal 
articles, clinical trial registries, and FDA reviews) or non-public (i.e., CSRs, CSR-Synopses, 
and IPD). Healthcare stakeholders interested in AEs often have access to only some of 
these sources, with very little guidance regarding their reliability and completeness. In 
this dissertation, we aim to explore how the use of different sources and different 
methods of reporting affect the conclusions regarding safety, using gabapentin for 
neuropathic pain and quetiapine for bipolar depression as case examples. 
Completeness and accuracy of adverse event reporting in different sources 
Despite the importance of safety, several studies have shown that harms are 
poorly reported in publications of RCTs covering a variety of medical disciplines (28-35). 
The quality of reporting is typically assessed by describing what information is and is not 
available in published literature. Some items that should be reported are collection 




(36). A systematic survey of RCTs in 2001 showed that 14% of trials did not mention 
safety at all, while another 32% either did not report results by arm or made only 
general statements (32). Despite the introduction of reporting guidelines (36), reporting 
has not improved significantly (33-35, 37). 
There has also been research comparing what data are available in different 
sources. Hartung et al compared AEs reported in a random sample of trials on 
ClinicalTrials.gov to those reported in publications. Discrepancies between the two 
sources were common, but there was no way of determining which source was more 
accurate without additional information (38). Other evidence suggests that trial 
registries may contain more information about AEs than journal articles (39-41). 
CSRs represent an important source of data about AEs. CSRs are comprehensive 
documents created by pharmaceutical companies for submission to regulatory agencies 
detailing the design, methods, analyses, and results of a single study (42). CSRs are then 
submitted to regulatory agencies to obtain approval for medications. In 1995, the 
International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) proposed guidelines for the structure and 
content of CSRs. The purpose of these guidelines was to “assist sponsors in the 
development of a report that is complete, free from ambiguity, well organised and easy 
to review” (42). CSRs should include detailed descriptions of study design, patient 




and individual patient data listings. CSRs are often thousands of pages in length and 
represent a largely untapped source of unpublished data (43, 44).  
The benefit of using CSRs in systematic reviews and meta-analyses was clearly 
demonstrated in the case of neuraminidase inhibitors (Tamiflu®). Conclusions regarding 
effectiveness changed when data from CSRs were included in the systematic review. 
There were also data in the CSRs about serious AEs that occurred in trials but were 
never reported in journal articles (45, 46). Other studies have compared CSRs with 
journal articles and found that much of the information in CSRs is not reported in 
journal articles (47, 48). One study compared AE reporting in CSRs, trial registries, and 
journal publications; CSRs were more complete than either trial registries or journal 
publications (49).  
Another source that is typically unavailable to the public is IPD. Because CSRs are 
produced only by pharmaceutical companies, IPD may provide access to typically 
unpublished data for non-industry trials. In one case study, Rodgers et al compared IPD 
with journal articles. They found that only 19.0% of AEs in the IPD were reported in 
journal articles (50).  
Filled out individual case report forms (forms used to collect data) represent 
another source of data. One case study (48) showed the benefit of using case report 
forms in a reanalysis of an RCT comparing paroxetine and imipramine to placebo. The 




both the CSR and the full publication. The results were concerning, particularly 
regarding AEs. For example, 159 AEs were recorded on the case report forms for 
patients in the paroxetine group, but only 136 AEs were recorded in the CSR. Although 
CSRs may be more comprehensive than some other sources of data, we must keep in 
mind that they do not necessarily represent a complete picture.   
Although there has been increasing research about the reporting of AEs in 
different data sources, there are some limitations to the current body of evidence. First, 
the vast majority of this research compares only two or three different data sources 
(e.g., journal articles vs. clinical trial registries). Without comparing all available types of 
sources, it is difficult to speak to the relative accuracy and completeness of different 
sources or provide guidance for their use in systematic reviews of AEs. In addition, the 
current research focuses almost exclusively on non-systematic AE reporting. 
Reporting bias 
After RCTs are conducted, their findings must be disseminated so that healthcare 
stakeholders can base their clinical decisions on the entire body of evidence; under-
reporting of research results has been classified by many as scientific misconduct (51-
53). People who volunteer to participate in RCTs do so with the understanding that their 
contribution will advance the field of medicine (53-55). Under-reporting the results of 
that research limits the advancement of science, so investigators have an obligation to 





RCTs may not be published (56-58) or reporting may be incomplete (58-63), 
however. For example, some outcomes may be reported while other outcomes remain 
unpublished. The Cochrane Handbook defines outcome reporting bias as “selective 
reporting of some outcomes but not others, depending on the nature and direction of 
the results” (64). Using quantitative results as a basis for determining reporting can 
impact the findings of systematic reviews and meta-analyses based on reported results 
(65-68). The presence of outcome reporting bias has been well-established for 
effectiveness outcomes (58-63). Although there is evidence that not all AEs are reported 
(38-40, 47-50, 69), little research has focused on how reported AEs are selected for 
reporting. The only guideline we have been able to identify related to selecting AEs for 
reporting is the Final Rule, which describes reporting requirements for ClinicalTrials.gov 
(5). The Final Rule states that non-systematic AEs that occurred in at least 5% of 
participants in any intervention group should be reported on ClinicalTrials.gov. The Final 
Rule also requires that all serious AEs be reported on ClinicalTrials.gov. We have been 
unable to identify any other research related to how AEs are selected for reporting. 
In addition to reporting only selected outcomes, sources may report incomplete 
information about an outcome. The Institute for Quality and Efficiency in Health Care 
(IQWiG) assessed outcomes reported in journal articles, trial registrations, and CSRs for 
completeness of reporting (70). An outcome was considered incompletely reported if 
results were not reported in enough detail to be included in a meta-analysis. For 




(e.g., confidence interval, standard error) would be considered incompletely reported. 
Similarly, a dichotomous outcome that reported the number of participants 
experiencing the AE (i.e., numerator), but not the total number of participants in the 
analysis (i.e., denominator) would be considered incompletely reported. Across all 
eligible trials in this study, 86% of outcomes were completely reported in CSRs, 
compared with 23% in journal articles and 22% in trial registrations (70). Incomplete 
reporting is problematic for systematic reviewers and meta-analysts, as well as other 
healthcare stakeholders who based their decisions on the results of systematic reviews. 
In one study, 55% of reviews were not able to include all eligible trials in the meta-
analysis of the review primary outcome (66). When outcomes are reported incompletely 
and cannot be included in meta-analyses, the summary effect estimates are not based 
on the entirety of the evidence.  
It has also been shown that journal articles about RCTs testing gabapentin for 
neuropathic pain report incomplete or different outcomes compared with CSRs (71). 
Primary outcomes (as defined in protocols) were unpublished or changed to secondary 
outcomes, secondary outcomes (as defined in protocols) were changed to primary 
outcomes for publication, and new primary outcomes were introduced in publications. 
Because reporting has been shown to be a problem for the effectiveness data, we 




Systematic reviews and meta-analyses of adverse events 
Although regulatory approval of drugs and biologics is typically based on the 
results of RCTs (4), RCTs are often not powered to detect differences in the frequency of 
AEs between interventions (72), because AEs are often rare. Systematic reviews and 
meta-analyses provide the opportunity to combine data about AEs from multiple RCTs. 
This may allow the detection of significant differences not identified in individual RCTs 
because combining data from several RCTs increases the power to detect differences 
(73). 
Systematic reviews and meta-analyses are crucial tools for collecting and 
combining the data that helps patients and clinicians make medical decisions. To help 
patients to make informed decisions regarding their medical care, it is important for 
them to have evidence about potential benefits as well as potential harms. Although 
systematic reviews focusing on AEs are becoming more common, they are still in the 
minority (29, 74-76).  
Systematic reviews of AEs usually do not include unpublished data (77). Data 
sharing is one method being used to combat the poor reporting of AEs. Data can be 
shared in many ways: on clinical trial registries (e.g., ClinicalTrials.gov, International 
Clinical Trials Registry Platform); directly with other investigators who request data (e.g., 
systematic reviewers who contact authors of journal articles directly to request data); 
on a public portal (e.g., ClinicalStudyDataRequest.com (78)); or on a private server or 




medications that are currently being prescribed were approved many years ago, many 
data sharing policies exclude data from older “legacy” trials. For example, the 
International Committee of Medical Journal Editors (ICMJE) began requiring trial 
registration for publication in 2005 (79). Similarly, ClinicalTrials.gov requires the 
registration of trials completed after 2007 (80). In addition, data-sharing policies on 
ClinicalStudyDataRequest.com vary by sponsor, but most require that trials were 
completed 2010 or later (78). This means that the reporting of AEs in publicly available 
sources (e.g., journal articles) becomes vitally important.  
Systematic reviews and meta-analyses can use data from a variety of sources: 
abstracts, journal articles, clinical trial registries, FDA reviews, CSRs, and IPD. Many 
systematic reviews include only journal articles. The Cochrane Handbook recommends 
searching for conference abstracts and unpublished literature (64). However, there is 
very little guidance on which sources to use when multiple sources offer different 
information.  
Objective and specific aims of this dissertation 
The overall objective of this dissertation is to address important research gaps 
related to the reporting of both non-systematic and systematic AEs and the potential for 





 Aim 1: Using RCTs examining gabapentin for neuropathic pain or quetiapine for 
bipolar depression, (a) compare the reporting of non-systematic AEs across all 
available sources (i.e., abstracts, journal articles, clinical trial registries, FDA 
reviews, CSRs, CSR-Synopses, and IPD) about RCTs and (b) assess how reporting 
patterns affect which evidence meta-analyses would be based on.  
 Aim 2: Using RCTs examining quetiapine for bipolar depression, (a) compare the 
reporting of systematic AEs across all available sources (i.e., abstracts, journal 
articles, clinical trial registries, FDA reviews, CSRs, CSR-Synopses, and IPD) about 
RCTs, (b) describe the completeness of reporting for systematic AEs in each data 
sources, and (c) assess how reporting patterns affect which evidence meta-
analyses would be based on. 
 Aim 3: Using RCTs examining gabapentin for neuropathic pain or quetiapine for 
bipolar depression, (a) compare reported methods for selecting which non-
systematic AEs to report both across multiple trials and across multiple sources 
for the same trial, (b) compare the non-systematic AEs reported in different 
sources that report using the same methods for selecting AEs for reporting, and 
(c) use simulated data to assess how using different “selection criteria” impacts 
the results of meta-analyses.  
Detailed methods and results for each of these aims are reported in the following three 




Datasets used in this dissertation 
This dissertation was conducted as a sub-study of the Multiple Data Sources 
(MUDS) study (81). All of the aims of this dissertation used data collected as part of the 
MUDS study. The aim of the MUDS study was to compare the reporting of RCTs in public 
and non-public sources, using gabapentin for neuropathic pain and quetiapine for 
bipolar depression as case examples. These two case examples were selected for several 
reasons. Both medications are very commonly used for the respective indications; this 
increases the clinical importance of the results. Originally, gabapentin was approved as a 
treatment for epilepsy, and has since been approved by the FDA for use in post-herpetic 
neuralgia; therefore, gabapentin is prescribed off-label for most neuropathic pain 
conditions. In contrast, quetiapine has been approved for multiple psychiatric 
conditions, including bipolar depression, so quetiapine is prescribed on-label (i.e., 
approved by the FDA for use in this indication). Gabapentin was also developed and 
approved by the FDA earlier than the quetiapine trials, and before many of the relevant 
policies about trial registration were in place. We did not expect most gabapentin trials 
to be registered, but we did expect many of the quetiapine trials to be registered. 
Having our case examples differ in these ways may help us to draw conclusions about 
RCTs more broadly. In addition, there is evidence of reporting bias related to both 
gabapentin and quetiapine (71, 82). 
We systematically searched PubMed, Embase, Lilacs, Cumulative Index to 




Controlled Trials (CENTRAL) for sources about gabapentin and quetiapine, as well as 
PsycInfo for sources about quetiapine, without language or date restrictions on March 
2, 2015 (gabapentin) and January 26, 2015 (quetiapine). We also searched certain 
conference proceedings and years for gabapentin trials (81). We searched the 
International Clinical Trials Registry Platform Search Portal (ICTRP) and the National 
Institute of Health (NIH) clinical trial registration platform (ClinicalTrials.gov) for trial 
registrations and associated results related to gabapentin or quetiapine on October 10, 
2014. We identified medical and statistical reviews of gabapentin for neuropathic pain 
and quetiapine for bipolar depression on the FDA website. We obtained non-public 
sources about gabapentin for neuropathic pain from unsealed litigation. We searched 
online (http://psychrights.org/) for typically non-public sources about quetiapine for 
bipolar depression. We requested additional non-public sources in the form of internal 
company documents from the manufacturers of gabapentin and quetiapine (Pfizer and 
AstraZeneca, respectively).  
The MUDS study identified 80 sources about 21 gabapentin trials and 52 sources 
about 7 quetiapine trials. For each source, we extracted extensive information that 
comprised the datasets used for this dissertation. Extracted data included information 
about baseline participant characteristics (e.g., sex, age, condition), interventions, 
duration of follow-up, trial funding, financial interests of the authors, effectiveness 




extractors also assessed the risk of bias for each source, using the Cochrane risk of bias 
tool (64). This dissertation focused solely on data related to AEs.  
Significance  
In order to make informed decisions regarding medical treatment, patients and 
clinicians need comprehensive and accurate information about the potential benefits 
and AEs of each intervention. RCTs provide a large amount of data that can be used to 
aid in decision making. Often, these data from RCTs are distilled into information in the 
form of systematic reviews and meta-analyses to facilitate easier consumption by 
clinicians, guideline developers, and other healthcare stakeholders (83).  
This doctoral dissertation aims to broaden the knowledge base about how AEs 
are collected and reported in RCTs, using gabapentin for neuropathic pain and 
quetiapine for bipolar depression as case examples.  
There has been research assessing reporting in different data sources covering a 
variety of comparisons: conference abstracts and journal articles (57, 84); conference 
abstracts and trial registries (85); trial registries and journal articles (38-41); CSRs and 
journal articles (47-49, 71, 86); and IPD and journal articles (48, 50, 87). However, only a 
subset of this research has been focused on AEs (38-41, 47-50), and nearly all AE 
research has focused on non-systematic AEs rather than systematic AEs. In addition, 




Aim 1 describes discrepancies in non-systematic AE data reported in conference 
abstracts, journal articles, clinical trial registries, FDA reviews, CSRs, CSR-Synopses, and 
IPD from RCTs testing gabapentin for neuropathic pain and quetiapine for bipolar 
depression. Our research broadens the existing evidence by comparing all available 
sources of data: conference abstracts, journal articles, clinical trial registries, FDA 
reviews, CSRs, CSR-Synopses, and IPD. We will also expand on the existing evidence by 
assessing whether non-systematic AE reporting is “complete” (i.e., data are reported in 
sufficient detail to be included in a meta-analysis) (70). If data about AEs differ across 
data sources, the information provided to healthcare stakeholders may be inaccurate. 
Aim 2 compares the reporting of systematic AE data in conference abstracts, 
journal articles, clinical trial registries, CSRs, CSR-Synopses, and IPD from RCTs examining 
quetiapine for bipolar depression. Aim 2 adds to the current body of evidence because 
research about AE reporting has focused almost exclusively on non-systematic AE 
reporting. AEs are only collected systematically if there is reason to suspect that they 
might be related to the intervention (5); thus, systematic AEs are likely to be clinically 
important. The lack of research related to their reporting is a gap in the current 
evidence.  
Aim 3 compares the consistency of “selection criteria” (i.e., the methods by 
which sources report that non-systematic AEs were selected for inclusion in the source) 
across trials and across sources about the same trial, as well as assessing the impact of 




reporting requirements (5), we were unable to identify any research related to assessing 
selection criteria for reporting non-systematic AEs. Aim 3 will attempt to fill this 




Figure 1-1. Theoretical Framework: Data sources about randomized controlled 
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Background: Clinicians, guideline developers, and other healthcare stakeholders must 
have access to the evidence about both effectiveness and adverse events (AEs) of 
potential health interventions to make informed clinical decisions. AEs identified in 
randomized controlled trials (RCTs) are poorly reported, and reporting may differ by 
data source. The objective of this study was to compare reporting, in public and non-
public sources, of non-systematic AEs (e.g., spontaneously reported by participants) 
observed in RCTs, including those designated by the Food and Drug Administration as 
“serious.”  
Methods and Findings: We performed a cross-sectional analysis using data from the 
Multiple Data Sources (MUDS) study, which examined sources of RCTs of gabapentin for 
neuropathic pain and quetiapine for bipolar depression (“eligible” RCTs). We identified 
public sources (i.e., journal articles, FDA reviews, trial registrations, conference abstracts 
and other short reports) and non-public sources (i.e., clinical study reports [CSRs], CSR-
synopses, and individual participant data [IPD]) available by March 2, 2015 (gabapentin) 
and January 26, 2015 (quetiapine). We extracted data about non-systematic AEs, 
including those categorized as “serious” or not, as reported by trial investigators. We 
compared reporting of non-systematic AEs across public and non-public sources. We 
counted the number of different AEs and serious AEs that were reported by source; for 




as reporting three different AEs. When AEs were reported in more than one source 
about the same trial, we compared the reported effect estimates. 
We identified 21 eligible gabapentin trials (80 sources) and seven eligible quetiapine 
trials (52 sources). On average, public sources reported fewer different AEs than non-
public sources (mean of 3 versus 121 and 3 versus 159 in public versus non-public 
sources, and for gabapentin and quetiapine, respectively). Most serious AEs were 
reported only in non-public sources (gabapentin: 56/72, 77%; quetiapine: 39/46, 85%). 
In rare cases when an AE was reported in multiple sources for the same trial, the effect 
estimates were similar.  
Conclusions: Non-systematic AEs, including serious AEs, were often unreported in public 
sources. Better reporting and open access to non-public data are needed so that clinical 
decision-makers can assess the balance of potential benefits and AEs and base their 






Patients, clinicians, and other decision makers need accurate and comprehensive 
information about potential benefits and adverse events (AEs) of healthcare 
interventions to inform decisions. AEs are defined by the Food and Drug Administration 
(FDA) as “any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related” (19). Health care decisions should be 
based on patient preferences and information about the balance of potential benefits 
and AEs for potential interventions.   
Randomized controlled trials (RCTs) are the reference standard for determining 
the effectiveness and AEs of an intervention. During an RCT, information about AEs can 
be collected using two primary methods. The first method has been described as the 
“non-systematic” approach by the Final Rule, which outlines federal reporting 
requirements for ClinicalTrials.gov (Table 2-1) (5, 6). Non-systematic AEs may be 
collected as a result of spontaneous reports by participants to investigators or as a 
result of open-ended questions such as “have you noticed any symptoms since your last 
visit?” Investigators collect “systematic” AEs by recording, in the same manner for each 
trial participant, information about symptoms and events that are suspected of being 
associated with an intervention at the time the study is conducted (Table 2-1).  
Although others distinguish between non-systematic and systematic AEs, some 
use different terminology. For example, the FDA uses “adverse events” to describe non-




AEs (20). In terms of AEs, regulatory approval of drugs and biologics by the FDA requires 
collection of information about an intervention’s effect on non-systematic AEs in RCTs, 
and is typically based on this information (4).  
Both non-systematic and systematic AEs can be classified as “serious,” an FDA 
classification that is standardized across trials. Serious AEs are defined by the FDA as 
“death, a life-threatening adverse event, inpatient hospitalization or prolongation of 
existing hospitalization, a persistent or significant incapacity or substantial disruption of 
the ability to conduct normal life functions, or a congenital anomaly/birth defect” (19, 
20).  
When patients are selecting a health intervention, they may be interested in the 
likely effectiveness as well as the different kinds of AEs and likelihood that they will 
experience the different AEs observed in trials. Yet, despite the importance of AEs to 
patients and clinicians, AEs are poorly reported in public sources across a variety of 
medical disciplines (28-34). Sources that are typically not publicly available (e.g., CSRs, 
individual participant data [IPD]) may contain more information about AEs than public 
sources (e.g., journal articles, conference abstracts) about the same trial (46, 48, 50, 69). 
For example, one case study showed that about 19% of AEs present in IPD were 
reported in journal articles (50). In addition, AE data may be publicly reported in some 
sources for a given trial but not in others (38, 39, 46, 48, 50, 69, 88, 89), or it can be 
inconsistently reported across sources for the same trial. Existing evidence typically has 




compare all available source types for a single trial. Comparing all available sources 
enables the description of the relative completeness of each source type; for example, 
do trial registries contain more complete and accurate information about AEs than 
journal articles?  
Our objectives in the current project were (1) to compare reporting of non-
systematic AEs, with a focus on serious AEs, in a wide variety of public and non-public 
sources for two case studies and (2) to assess whether AE effect estimates vary among 
different sources. Our case studies were gabapentin for neuropathic pain and 
quetiapine for bipolar depression. 
Methods 
This analysis is a sub-study of the Multiple Data Sources (MUDS) study, a cross-
sectional study that compares reporting of RCTs in public and non-public sources. The 
protocol (81) and protocol amendments (90) provide additional details about the MUDS 
study methods. We have also reported additional details in Appendix 2-1. 
Eligible trials and sources 
Briefly, eligible studies were parallel RCTs that compared either gabapentin for 
neuropathic pain in adults or quetiapine for bipolar depression in adults with placebo; 
participants and providers were masked. We use “public sources” to refer to journal 
articles, short reports (i.e., conference abstracts, commentaries, posters), trial 
registrations and associated results, and medical and statistical reviews created by the 




and IPD, because they are usually not available to the public. We searched for public 
and non-public sources and requested additional non-public sources from the company 
that manufactures quetiapine (see Appendix 2-1 and protocol (81) for additional 
details).  
Data extraction  
We classified AEs as systematic or non-systematic (5, 6). We pre-specified that 
we would classify AEs as systematic when they were reported as being obtained using 
specific measurement tools such as questionnaires, checklists, laboratory tests, and 
clinical examinations that were done on every patient. All other AEs were classified as 
non-systematic. Our analysis in this study focused exclusively on non-systematic AEs.  
Two investigators independently extracted data about AEs using the open access 
Systematic Review Data Repository (SRDR; http://srdr.ahrq.gov/) and resolved any 
differences by discussion. We extracted the name of the non-systematic AE (e.g., 
dizziness, headache) and the associated results, such as the number or proportion of 
participants experiencing an AE, if available. We extracted results that were reported 
separately for each trial, and therefore did not extract data that were pooled from 
multiple trials. We extracted information about AEs even when results were not 
reported; for example, if a source reported that “the most common AEs were dizziness 
and headache,” we extracted dizziness and headache as reported AEs. We extracted AE 
results closest to 8 and 18 weeks. We also extracted whether the source described the 




Reanalysis of IPD 
We did not receive meta-data (e.g., codebooks) for the IPD we obtained through 
litigation, making it difficult to interpret variables and the data contained in them. We 
used information in the corresponding CSRs (e.g., case report forms) to determine the 
meaning of the variables in the IPD. When databases were not available, we used ABBYY 
FineReader (91) to reconstruct databases using tables of IPD (in PDF format) in the 
appendices of CSRs. When both the IPD and CSR were available, we reanalyzed IPD data 
to assess agreement with what was reported in the associated CSR, replicating the 
methods for handling missing data used in the original trials. Using the IPD, we 
calculated the number of participants who experienced: (1) each named non-systematic 
AE, (2) each named serious non-systematic AE, (3) ≥1 non-systematic AE, and (4) ≥1 
serious non-systematic AE. We performed all analyses using Stata 14 (92). 
Comparing AEs across sources 
To understand whether the reporting of non-systematic AEs was consistent 
across sources, we made the following comparisons: whether the non-systematic AE 
information was from a (1) public vs. non-public source, (2) journal article vs. non-public 
source, and (3) journal article vs. other public source. We compared the number of 
sources that reported non-systematic AEs and serious AEs. We also counted and 
compared the number of different non-systematic AEs and serious non-systematic AEs 
in each source. For example, if a source contained information about dizziness, 




we compared the average number of different non-systematic AEs and serious non-
systematic AEs reported in each source (e.g., the average number of different non-
systematic AEs reported in journal articles across trials). For each individual trial, we 
compared the number of different non-systematic AEs and serious non-systematic AEs 
in public sources and non-public sources and used a Pearson’s chi-squared test to 
examine statistical significance of our findings.  
We anticipated that we would be able to obtain non-public sources for industry-
funded trials only; CSRs and CSR-synopses are produced for industry trials, but not non-
industry trials, and we did not request IPD separately from CSRs. To assess whether 
reporting of AEs was similar in trials with and without industry funding, we compared 
the mean number of different AEs reported in journal articles by industry funding and 
used a two-sided Student’s t-test to examine statistical significance of our findings. 
To assess whether different sources about the same trial reported the same 
results, we compared effect estimates (e.g., proportion of participants experiencing the 
AE) reported in different sources about the same trial. We created plots that showed all 
effect estimates for (1) experiencing any non-systematic AE(s) and (2) experiencing any 
serious non-systematic AE(s) in those taking gabapentin or quetiapine compared with 
placebo. For these plots, we combined the results from different doses of gabapentin or 
quetiapine from the same trial. For example, for a three-arm trial that compared 1800 
milligrams (mg) gabapentin, 3600 mg gabapentin, and placebo, we combined the results 




For a trial’s results to be considered “meta-analyzable” (90), the source had to 
report at least two of the following three pieces of information separately for each arm 
in the trial: number of participants experiencing the AE, percent of participants 
experiencing the AE, and number of participants analyzed. We considered information 
in IPD meta-analyzable. We assessed, for each different AE, how many trials reported 
meta-analyzable AE results and whether we could calculate the summary between 
groups effects (e.g., risk difference, relative risk) for each reported non-systematic AE. 
We compared summary data from all sources and summary data with non-public 
sources removed, to assess how excluding non-public sources would affect meta-
analytic findings.  
Results 
Search results 
We identified 80 sources (including six IPD) for 21 gabapentin trials and 52 
sources (including two IPD) for 7 quetiapine trials (Appendix Figure 2-1). One gabapentin 
trial had no public source. Of the sources we identified, most were public: 68/80 (85%) 
for gabapentin and 46/52 (88%) for quetiapine. Most public sources were short reports 
(gabapentin: 35/68, 51%; quetiapine: 24/46, 52%), followed by journal articles 
(gabapentin: 26/68, 38%; quetiapine: 15/46, 33%). The majority of trials we identified 





We requested CSRs and IPD from Pfizer, the company that bought the 
companies that originally supported nine gabapentin trials, but had not received any 
data from them by October 16, 2017. Although we requested additional CSRs and IPD 
from Astra Zeneca, the company performing all seven quetiapine trials, our request was 
denied (93). 
We used CSRs and IPD available from unsealed litigation for 6/9 gabapentin 
trials; the IPD were electronic and in database format. We obtained CSRs for two trials 
and CSR-synopses for two quetiapine trials by searching online 
(http://psychrights.org/).The first CSR included extensive IPD tables. Based on other 
information in the second CSR, we know that the IPD tables in the second CSR did not 
contain data about all the non-systematic AEs that occurred in the trial. Rather, the IPD 
tables containing non-systematic AEs included serious AEs, AEs leading to withdrawal 
from the study, and AEs “of interest.”  
Comparing reanalyzed IPD with CSRs 
We identified discrepancies between CSRs and IPD for the same trial. For 5/6 
gabapentin trials and both quetiapine trials, we identified more different AEs in the CSR 
than in the IPD; in addition, there were many AEs in the IPD that we were unable to 
identify. For one gabapentin trial (A945-1008), there appeared to be many discrepancies 
between the CSR and IPD. The CSR for this trial reported that the summary data in the 
CSR and the IPD were coded for analysis using different methods, so it is expected that 




Public sources underreported non-systematic adverse events 
On average, public sources described fewer different AEs than non-public 
sources (gabapentin: mean of 3 vs. 121 different AEs; quetiapine: mean of 3 vs. 159 
different AEs). Across all eligible trials, a total of 341/419 (81%) and 436/471 (93%) 
different AEs were reported only in non-public sources for gabapentin and quetiapine, 
respectively (Appendix Table 2-1). Similarly, the majority of different serious AEs were 
reported only in non-public sources: 56/72 (78%) in gabapentin trials and 39/46 (85%) in 
quetiapine trials.  
The mean number of different AEs reported varied by source, even when the 
sources compared were all public or all non-public. Journal articles described a mean of 
5 and 7 different AEs, while other public sources, such as ClinicalTrials.gov, reported a 
mean of 3 and 2 different AEs, for gabapentin and quetiapine respectively. FDA reviews 
reported AE data pooled from multiple trials so we could not analyze the information. 
CSR-synopses reported a mean of 19 different AEs, while CSRs reported a mean of 123 
and 297 different AEs for gabapentin and quetiapine, respectively. 
For both gabapentin and quetiapine, public sources frequently omitted data 
about non-systematic AEs that were almost always present in non-public sources (Figure 
2-1, Table 2-2). For example, 8/68 (12%) public gabapentin sources and 4/46 (9%) public 
quetiapine sources reported the number of participants who experienced any AE, 
compared with 12/12 (100%) and 6/6 (100%) non-public sources and the number of 




(Figure 2-1, Table 2-2). Journal articles reported data about non-systematic AEs more 
often than other public sources, but still less often than non-public sources (Table 2-3).  
When we compared public with non-public sources about the same trial (6 trials 
for gabapentin and 4 trials for quetiapine had both types of sources), we found that 
public sources contained data about significantly fewer non-systematic AEs (Pearson’s 
chi square, p<0.001 for both gabapentin and quetiapine). Whereas public sources 
typically reported few different AEs, non-public sources reported hundreds of different 
AEs about the same trial (Figure 2-2). We also found that public sources reported fewer 
different serious AEs compared to non-public sources (Pearson’s chi square, p<0.001 for 
both gabapentin and quetiapine). Whereas public sources reported serious AEs for 2/10 
trials, 10/10 non-public sources reported serious AEs.  
Because CSRs (non-public) are produced only for industry trials, we could not 
compare the number of different AEs reported in public sources with non-public sources 
for trials without industry funding. When we compared the number of different AEs 
reported in journal articles about 27 (20 gabapentin and 7 quetiapine) trials with and 
without industry funding, we found no evidence of a difference. Journal articles about 
trials with industry funding reported an average of 6 (standard deviation=6) different 
non-systematic AEs, while journal articles about trials without industry funding reported 




Meta-analyses of adverse event data from public sources would include few trials 
When effect estimates for non-systematic AEs for one trial appeared in multiple 
sources, the estimates were similar or identical to one another (Figure 2-3). We were 
rarely able to compare the estimates in public and non-public sources; public sources 
often did not report the data, and non-public sources were often unavailable.  
Even when meta-analyzable data on non-systematic AEs were available, they 
were not usually available in a public source (Appendix Table 2-1). Meta-analyzable 
results were reported only in non-public sources for 349/411 (85%) and 439/462 (95%) 
different non-systematic AEs for gabapentin and quetiapine, respectively (Appendix 
Table 2-1). Similarly, meta-analyzable results were reported only in non-public sources 
for 54/70 (77%) and 37/38 (97%) different serious AEs. 
Without non-public sources such as CSRs and IPD, meta-analyses of AE data were 
largely impossible or could include few trials (Appendix Tables 2-2 and 2-3). For 
example, if a meta-analysis were conducted of the risk of experiencing any non-
systematic AE comparing gabapentin or quetiapine with placebo, 9/21 and 6/7 trials 
could be included. When we limited the meta-analyses to data from public sources, the 
meta-analyses included 5/21 gabapentin trials and 3/7 quetiapine trials. We found 
similar results when examining the number of participants who experienced any serious 





Compared with non-public sources, public sources reported fewer different non-
systematic AEs occurring in gabapentin and quetiapine trials. The majority of AEs were 
reported only in non-public sources. Almost all AE data in non-public sources were 
meta-analyzable, while few AEs reported in public sources were. We have demonstrated 
that, for these two interventions, using public sources alone would result in healthcare 
stakeholders lacking information about most non-systematic AEs. 
Similarly, most serious AEs were not described at all in public sources, implying 
that most patients and their doctors would not have this knowledge. When serious AEs 
were reported in public sources, they were often not meta-analyzable, meaning that 
researchers would not be able to assess the likelihood that patients would experience 
each different serious AE. Journal articles, which typically serve as the main source of 
data for clinical decision-makers, reported little or no data about serious AEs. When 
serious AEs are unreported in public sources, clinical decision-makers lack information 
critical to selecting an intervention. 
Public sources frequently did not report the number of participants who 
described having any non-systematic AE or any non-systematic serious AE. When AE 
data were reported in both public and non-public sources about the same trial, the 
effect estimates were similar. We frequently could not compare public and non-public 
sources, however, because of serious under-reporting in the public sources and 




Although we examined only two interventions and indications in our analysis, we 
believe our findings may apply to other interventions. Our findings were similar for both 
interventions, despite the differences in indication, drug class, and time-period of the 
eligible trials. In addition, our findings are consistent with previous studies that 
compared public and non-public sources (46, 48, 50, 69). In contrast, our results differ 
from studies that showed ClinicalTrials.gov to be more complete than journal articles 
(38, 39, 89); we found ClinicalTrials.gov may not be a good source of information about 
AEs when the trials were conducted before registration was required by funders and 
journal editors (79).  
CSR-synopses do not contain much more information than public sources and 
should not be considered an acceptable substitute for CSRs or IPD for examining non-
systematic AEs. CSRs reported meta-analyzable data where CSR-synopses did not, and 
CSRs and IPD both reported many more non-systematic AEs and serious AEs than CSR-
synopses. FDA reviews were also not a good source of data about non-systematic AEs; 
while they did contain data about AEs, the data were pooled across trials, rather than 
reported separately for each trial. 
A limitation of our study is that we identified non-public sources only for 
industry-funded trials, so we could not compare public with non-public sources for trials 
with other funding. Reporting of non-systematic AEs was similar in journal articles about 
RCTs with and without industry funding, however. Therefore, underreporting of AEs 




Because CSRs are available only for industry trials, IPD may provide the additional 
information about AEs in non-industry trials needed to make informed healthcare 
decisions, as long as the meta-data (e.g., codebooks) for the IPD are provided. 
It is important for patients to be able to use information about benefits and AEs 
to inform their healthcare decisions, for example, using “scenario planning” (94). This 
involves the doctor discussing best, worst, and mostly likely scenarios following 
treatment. For example, the “worst” scenario for gabapentin or quetiapine might be 
that the treatment doesn’t show any benefit and also causes some harm AEs. The “best” 
scenario might be that the patient’s symptoms are completely alleviated and they 
experience no AEs. The most likely scenario may involve some benefit and some harm. 
The doctor and patient can discuss what the likely AEs are and whether these may 
outweigh the likely benefits, as well as how scenarios may differ across treatment 
options. Doctors must have comprehensive information about both benefits and harms 
in order to construct the different scenarios. When harms are not reported in public 
sources, doctors may be unable to describe the likelihood of the worst scenario or 
compare scenarios for different treatment options.  
 “Open science” and data sharing present a possible way to address poor 
reporting of AEs. Data can be shared in many ways: on clinical trial registries (e.g., 
ClinicalTrials.gov); directly with other investigators who request data (e.g., systematic 
reviewers who contact authors of journal articles to request data); on a public portal 




many commonly prescribed medications currently in use were approved many years 
ago, many data sharing policies exclude older trials, so obtaining relevant data can be 
difficult. For example, ClinicalTrials.gov only requires the registration of trials completed 
after 2007 (80). The International Committee of Medical Journal Editors (ICMJE) 
required trial registration for publication starting in 2005 (79). Data sharing on public 
portals may also be limited to trials completed after a certain date. On 
ClinicalStudyDataRequest.com, for example, data-sharing policies vary by trial sponsor, 
but most date requirements are 2010 or later (78).  
Our findings demonstrate the need for open science and data sharing to combat 
the poor reporting of AEs, not only for new trials, but older trials about medications that 
are widely used in medical practice (95). Currently, non-public sources, especially for 
older trials, can be difficult to obtain. Non-public sources can also be difficult to use. 
While it took only a few hours to extract data from each journal article, it took weeks to 
extract all trial data from the CSRs we obtained, which were an average of 2900 pages 
long. In addition, since we did not receive meta-data (e.g., codebooks) for IPD, we spent 
months deciphering the meaning of the variables in the databases we received. Even 
with extensive work, there were some variables that we could not identify. In our 
analysis, where it was not necessary to perform additional analyses using IPD (e.g., 
subgroup analyses not performed during the original trial analysis), the aggregate data 
provided in CSRs were much easier to use and provided just as much or more 




from CSRs or analyze IPD without appropriate meta-data, CSRs and IPD provide a much 
more complete picture of the potential harms of a medication than journal articles or 
CSR-synopses. With access to currently non-public sources, all healthcare stakeholders 





Table 2-1. Glossary of Terms 






Adverse events that are collected using open-ended questions or are 
spontaneously reported by participants. For example, adverse events 
collected by asking participants questions like “Have you noticed any 




Adverse events that are collected in the same manner for each participant 
using methods related to specific adverse events. For example, adverse 
events collected using validated questionnaires, checklists, laboratory 
measurements, or vital signs.  
 Serious 
adverse events 
AEs classified according to definitions determined by regulatory agencies. 
The Food and Drug Administration and European Medicines Agency define 
serious AEs as “death, a life-threatening adverse event, inpatient 
hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or a congenital anomaly/birth defect” (19).  
Sources 
 Public sources In this study, public sources include journal articles, conference abstracts, 
commentaries, posters, trial registrations and associated results, and 




In this study, non-public sources include individual patient data, clinical 
study reports, and clinical study report-synopses. 
 Clinical study 
report (CSR) 
A comprehensive document created by a pharmaceutical company detailing 
the design, methods, analyses, and results of a single study for submission 
to regulatory agencies. The clinical study reports we examined ranged in 
length from 1315 to 8027 pages. Appendices contain tables of individual 
participant data, also called “patient data listings.”  




An internal company document that summarizes the information contained 
in clinical study reports. Clinical study report-synopses are much shorter 
than clinical study reports; the two clinical study report-synopses we 




Each record lists data separately for each participant. In the below example, 
the data include a participant identifier (“PTNO”), text describing the 
adverse event (“AETX”), whether the AE was classified as serious (“AESER”), 
the day of the study that the event occurred (“SDAESTDY”), and a 
standardized code for grouping AEs that are clinically equivalent (“AE”; e.g., 
“giddy” and “giddiness” have the same code). There is a separate record for 
each participant and each different AE. For example, participant 167 











Table 2-2. Number of public and non-public sources with information about non-
systematic adverse events 
Table 2-2 Legend: Each source is counted only once, regardless of whether the source describes one 
adverse event or more than one adverse event). Public sources include journal articles, conference 
abstracts, FDA reviews, trial registrations, and other short reports (i.e., letters to the editor, posters, press 
releases, reports in trade publications). Non-public sources include clinical study reports (CSRs), CSR-
synopses, and individual participant data (IPD).  
AE = adverse event; N = total number of sources (e.g., there are 68 public sources for gabapentin); n = 
number of sources describing each characteristic by category (e.g., 8/68 public sources for gabapentin 
described participants who experienced any adverse event; 7/68 public sources described participants 




Quetiapine for bipolar 
depression 









    N=68 N=12 N=46 N=6 
Number of sources including AE data n (%) n (%) n (%) n (%) 
  Participants experiencing ≥1 AE 8 (12%) 12 (100%) 4 (9%) 6 (100%) 
  Specific adverse events 31 (46%) 12 (100%) 22 (48%) 6 (100%) 
  Participants experiencing ≥1 serious AE 9 (13%) 12 (100%) 6 (13%) 6 (100%) 
  Specific serious adverse events 4 (6%) 12 (100%) 1 (2%) 6 (100%) 
Number of sources including meta-
analyzable AE data 
                
  Participants experiencing ≥1 AE 7 (10%) 12 (100%) 3 (7%) 6 (100%) 
  Specific adverse events 18 (26%) 12 (100%) 7 (15%) 6 (100%) 
  Participants experiencing ≥1 serious AE 4 (6%) 12 (100%) 4 (9%) 6 (100%) 






Table 2-3. Number of journal articles and other public sources with information 
about non-systematic adverse events 
Table 2-3 Legend: Each source is counted only once, regardless of whether the source describes one 
adverse event or more than one adverse event). Other public sources include conference abstracts, FDA 
reviews, trial registrations, and other short reports (i.e., letters to the editor, posters, press releases, 
reports in trade publications).  
AE = adverse event; N = total number of sources (e.g., there are 26 journal articles for gabapentin); n = 
number of sources describing each characteristic by category (e.g., 7/26 journal articles for gabapentin 




Quetiapine for bipolar 
depression 









    N=26 N=42 N=15 N=31 
Number of sources including AE data n (%) n (%) n (%) n (%) 
  Participants experiencing ≥1 AE 7 (27%) 1 (2%) 2 (13%) 2 (6%) 
  Specific adverse events 18 (69%) 13 (31%) 11 (73%) 11 (35%) 
  Participants experiencing ≥1 serious AE 6 (23%) 3 (7%) 5 (33%) 1 (3%) 
  Specific serious adverse events 3 (12%) 1 (2%) 1 (7%) 0 (0%) 
Number of sources including meta-
analyzable AE data 
              
  Participants experiencing ≥1 AE 6 (23%) 1 (2%) 2 (13%) 1 (3%) 
  Specific adverse events 14 (54%) 4 (10%) 6 (40%) 1 (3%) 
  Participants experiencing ≥1 serious AE 2 (8%) 2 (5%) 3 (20%) 1 (3%) 






Figure 2-1. Number of trials reporting or recording participants experiencing any 
non-systematic adverse event 
Figure 2-1 Legend: Data were considered “meta-analyzable” when a between group effect could be 
calculated (e.g., both the number of participants experiencing an adverse event and the number of 
participants analyzed were reported). 
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Figure 2-2. Number of different non-systematic adverse events reported in public 
and non-public sources by trial 
Figure 2-2 Legend: Note: the axes are different for each panel to make the figure easier to read and 
numbers of different AEs for each source provided by trial. Public sources include journal articles, 
conference abstracts, Food and Drug Administration reviews, trial registrations, and other short reports. 
Non-public sources include clinical study reports (CSRs), CSR-synopses, and individual participant data 
(IPD). This figure includes CSRs and IPD for all gabapentin trials and Calabrese 2004 and Thase 2006 
(quetiapine trials). This figure includes only CSR-synopses for McElroy 2010 and Young 2008.  
No. of different AEs: Number of different specific AEs reported in each source. For example, if a source 
contained data about dizziness, confusion, and somnolence, the number of different adverse events 
would be 3. This includes adverse events that are described without numerical data (i.e., ranged from a 
mention to data that were not meta-analyzable to meta-analyzable data). 
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Trials with non-public sources 
2-2a. Gabapentin: No. of different AEs 





































Trials with non-public sources 


















































Trials with non-public sources 










































Trials with non-public sources 




Figure 2-3. Relative risk (95% confidence interval) of experiencing any non-
systematic adverse event comparing gabapentin or quetiapine with placebo, by 
trial and source 
Figure 2-3 Legend: Public sources include journal articles, conference abstracts, FDA reviews, trial 
registrations, and other reports (i.e., letters to the editor, posters, press releases, reports in trade 
publications). Non-public sources include clinical study reports (CSRs), CSR-synopses, and individual 
participant data (IPD). Panel 2-3a shows only the 9/21 gabapentin trials for which we could calculate the 
relative risk from data in at least one source. The remaining 12/21 gabapentin trials did not report meta-
analyzable data for the number of participants experiencing any adverse event in any data source. We did 
not have non-public sources for any of these 12 trials. Panel 2-3b shows only the 6/7 trials for which we 
could calculate the relative risk from data in at least one source. The remaining trial did not report meta-
analyzable data for the number of participants experiencing any adverse event in any data source. We did 
not have non-public sources for this trial. Not all trials have data from all sources; for example, we could 
only calculate the relative risk and 95% confidence interval for Backonja 1998 using the CSR and IPD.  
CSR = clinical study report; IPD = individual participant data; RR = relative risk; CI = confidence interval 











































































































































































Appendix 2-1. Detailed methods 
Identifying sources about eligible trials 
We searched both the International Clinical Trials Registry Platform Search Portal (ICTRP) and 
ClinicalTrials.gov for trial registrations and associated results related to gabapentin or quetiapine on 
October 10, 2014. We searched PubMed, Embase, Lilacs, CINAHL and the Cochrane Central Register of 
Controlled Trials (CENTRAL) for gabapentin and quetiapine sources, as well as PsycInfo for quetiapine; we 
completed our searches March 2, 2015 (gabapentin) and January 26, 2015 (quetiapine), without any 
language restrictions. We identified medical and statistical reviews of gabapentin as well as quetiapine 
available on the FDA website (31). We also searched certain conference proceedings and years for 
gabapentin trials (see protocol (1)). We searched online (http://psychrights.org/) for typically non-public 
sources about quetiapine for bipolar depression. We requested non-public sources in the form of internal 
company documents from the manufacturers of gabapentin and quetiapine (Pfizer and AstraZeneca, 






Appendix Table 2-1. Number of different adverse events reported by trial and source 
Appendix Table 2-1 Legend: This table shows, by trial and source, the number of different adverse events and the number of different adverse events that 
were reported in enough detail to be included in a meta-analysis.  
1
 CSR-synopses (CSR-S) were available only for quetiapine. FDA reviews were available only for gabapentin. 
1 trial = journal article about a single eligible trial; ≥2 trials = journal article about two or more eligible trials; Abstract = conference abstract; Registration= trial 
registration on ClinicalTrials.gov or another registry; FDA = Food and Drug Administration medical or statistical review; Other = letters, summaries of journal 
articles, press releases, brief reports in trade publications (e.g., not peer reviewed); CSR-S = clinical study report-synopsis; CSR = clinical study report; IPD = 
individual participant data; N/A = not applicable because there are no reports. 
Different adverse events: Number of different specific adverse events reported in each source. For example, if a source contained data about dizziness, 
confusion, and somnolence, the number of different adverse events would be three. This includes adverse events that are described without numerical data 
(e.g., the most common adverse events were headache and nausea). Different adverse events with meta-analyzable data: Number of different adverse events 
for which the between group effect size could be calculated (e.g., source reported number of participants with the AE and the total number analyzed). 
  Public Sources Non-Public Sources 
All 
Sources 









 CSR IPD 
All Non-
Public Trial Identifier 1 Trial >1 Trial Abstract Other 
 Different adverse events (Different adverse events with meta-analyzable data) 
Gabapentin for neuropathic pain 
945-224 (96-101) N/A 2 (0) 0 (0) 0 (0) N/A N/A 2 (0) N/A 97 (97) 86 (86) 102 (102) 102 (102) 
A945-1008 (102) N/A N/A N/A N/A N/A N/A N/A N/A 199 (199) 210 (210) 287 (287) 287 (287) 
Arai 2010 (103, 104) 3 (3) N/A 1 (0) N/A N/A N/A 4 (3) N/A N/A N/A N/A 4 (3) 
Backonja 1998 (96-100, 105-113) 7 (6) 2 (0) 3 (0) 3 (0) N/A N/A 7 (6) N/A 97 (97) 91 (91) 100 (100) 101 (100) 
Caraceni 2004 (114-116) 26 (25) N/A N/A 24 (24) N/A N/A 26 (26) N/A N/A N/A N/A 26 (26) 
Hahn 2004 (117) 5 (5) N/A N/A N/A N/A N/A 5 (5) N/A N/A N/A N/A 5 (5) 
Hui 2010 (118, 119) 7 (0) N/A N/A N/A 0 (0) N/A 7 (0) N/A N/A N/A N/A 7 (0) 
Irving 2009 (120, 121) 12 (9) N/A N/A N/A N/A N/A 12 (9) N/A N/A N/A N/A 12 (9) 
Milenkovic 2009 (122) N/A N/A 0 (0) N/A N/A N/A 0 (0) N/A N/A N/A N/A 0 (0) 
Mishra 2012 (123) 0 (0) N/A N/A N/A N/A N/A 0 (0) N/A N/A N/A N/A 0 (0) 
NCT00475904 (124) N/A N/A N/A N/A 1 (1) N/A 1 (1) N/A N/A N/A N/A 1 (1) 
Rice 2001 (96-100, 125-132) 12 (12) 3 (0) 0 (0) 0 (0) N/A 1 (0) 12 (12) N/A 113 (109) 104 (104) 114 (110) 114 (111) 
Rowbotham 1998 (96-100, 125-128, 
133-136) 




Sandercock 2012 (137-139) 6 (1) N/A N/A 2 (0) 0 (0) N/A 6 (1) N/A N/A N/A N/A 6 (1) 
Sang 2013 (140-156) 6 (6) 0 (0) 2 (2) 0 (0) 26 (26) N/A 26 (26) N/A N/A N/A N/A 26 (26) 
Serpell 2002 (96-100, 128, 157-160) 10 (10) 2 (0) 0 (0) 0 (0) N/A N/A 10 (10) N/A 114 (111) 103 (103) 115 (112) 115 (112) 
Simpson 2001 (161, 162) 6 (6) N/A 0 (0) N/A N/A N/A 6 (6) N/A N/A N/A N/A 6 (6) 
Tamez Pérez 2000 (163, 164) 0 (0) N/A N/A 1 (0) N/A N/A 1 (0) N/A N/A N/A N/A 1 (0) 
Wallace 2010 (140-152, 165-167) 6 (6) 0 (0) 0 (0) N/A 0 (0) N/A 6 (6) N/A N/A N/A N/A 6 (6) 
Yildirim 2003 (168) 2 (0) N/A N/A N/A N/A N/A 2 (0) N/A N/A N/A N/A 2 (0) 
Zepeda Vazquez 2001 (169) 4 (4) N/A N/A N/A N/A N/A 4 (4) N/A N/A N/A N/A 4 (4) 
Total 51 (47) 5 (0) 4 (2) 28 (24) 26 (26) 1 (0) 68 (62) N/A 304 (297) 329 (329) 391 (384) 419 (411) 
Quetiapine for bipolar depression 
Calabrese 2004 (170-195) 13 (10) 1 (0) 5 (0) 0 (0) 0 (0) N/A 13 (10) N/A 319 (319) 316 (316) 321 (321) 324 (322) 
Gao 2014 (196, 197) 9 (9) N/A N/A N/A 8 (8) N/A 9 (9) N/A N/A N/A N/A 9 (9) 
Li 2014 (198, 199) N/A N/A N/A N/A 0 (0) N/A 5 (0) N/A N/A N/A N/A 5 (0) 
McElroy 2010 (170-176, 200-204) 22 (15) 0 (0) 7 (0) 0 (0) 0 (0) N/A 22 (15) 27 (15) N/A N/A 27 (15) 29 (16) 
Suppes 2010 (205-207) 15 (14) N/A 3 (0) N/A 0 (0) N/A 15 (14) N/A N/A N/A N/A 15 (14) 
Thase 2006 (170-180, 208-213) 11 (8) 1 (0) 0 (0) 2 (0) 0 (0) N/A 12 (8) N/A 275 (275) 9 (9) 275 (275) 279 (275) 
Young 2008 (170-176, 200, 214-219) 11 (10) 0 (0) 4 (0) 1 (0) 0 (0) N/A 12 (10) 11 (11) N/A N/A 11 (11) 13 (11) 





Appendix Table 2-2. Gabapentin trials with data that could be included in a meta-
analysis, by whether the data source is public 
Appendix Table 2-2 Legend: For example, when including data from any source, 6/21 (29%) trials reported 
meta-analyzable results for the number of participants who experienced abdominal pain. When including 
only data from public sources, 1/21 (5%) trials reported meta-analyzable results for the number of 
participants who experienced abdominal pain. 
The first section of the table includes the number of participants experiencing any AE(s) and the number 
of participants experiencing any serious AE(s).  
The second section of the table includes specific adverse events (in alphabetical order) for which meta-
analyzable data were reported in a public source for at least one trial, followed by specific adverse events 
(in alphabetical order) for which meta-analyzable data were not reported in any public sources.  
The third section of the table includes specific serious adverse events (in alphabetical order) for which 
meta-analyzable data were reported in a public source for at least one trial, followed by specific serious 
adverse events (in alphabetical order) for which meta-analyzable data were not reported in any public 
sources.  
  Gabapentin for neuropathic pain (N=21 trials) 
  
Trials with meta-analyzable 
data across all sources 
No. (%) 
Trials with meta-analyzable 
data across public sources 
No. (%) 
Aggregated adverse events 
  No. participants experiencing ≥1 AE 9 (43%) 5 (24%) 
  No. participants experiencing ≥1 serious AE 9 (43%) 4 (19%) 
Named adverse events 
  Abdominal Pain 6 (29%) 1 (5%) 
  Accidental Injury 6 (29%) 1 (5%) 
  Asthenia 6 (29%) 1 (5%) 
  Ataxia 6 (29%) 1 (5%) 
  Confusion 7 (33%) 2 (10%) 
  Constipation 7 (33%) 1 (5%) 
  Death 4 (19%) 3 (14%) 
  Diarrhea 7 (33%) 4 (19%) 
  Dizziness 11 (52%) 9 (43%) 
  Dry Mouth 8 (38%) 3 (14%) 
  Edema Peripheral 9 (43%) 5 (24%) 
  Fatigue 2 (10%) 1 (5%) 
  Flu Syndrome 6 (29%) 1 (5%) 
  Gait Ataxia 1 (5%) 1 (5%) 
  Gait Disturbance 1 (5%) 1 (5%) 
  Headache 12 (57%) 8 (38%) 
  Infection 6 (29%) 2 (10%) 
  Nasopharyngitis 1 (5%) 1 (5%) 
  Nausea 12 (57%) 8 (38%) 
  Pain 6 (29%) 1 (5%) 
  Sedation 1 (5%) 1 (5%) 




  Upper Respiratory Tract Infection 2 (10%) 1 (5%) 
  Vertigo 5 (24%) 1 (5%) 
  Abnormal Dreams 4 (19%) 0 (0%) 
  Abnormal Gait 3 (14%) 0 (0%) 
  Abnormal Stools 2 (10%) 0 (0%) 
  Abnormal Vision 4 (19%) 0 (0%) 
  Abscess 2 (10%) 0 (0%) 
  Accidental Fall 1 (5%) 0 (0%) 
  Acne 3 (14%) 0 (0%) 
  Agitation 2 (10%) 0 (0%) 
  Akinesia 1 (5%) 0 (0%) 
  Albuminuria 1 (5%) 0 (0%) 
  Alkaline Phosphatase Increased 1 (5%) 0 (0%) 
  Allergic Reaction 2 (10%) 0 (0%) 
  Allergy Aggravated 1 (5%) 0 (0%) 
  Alopecia 2 (10%) 0 (0%) 
  Altered Bowel Habit 1 (5%) 0 (0%) 
  Amblyopia 5 (24%) 0 (0%) 
  Amnesia 6 (29%) 0 (0%) 
  Anemia 3 (14%) 0 (0%) 
  Angina Pectoris 3 (14%) 0 (0%) 
  Anorexia 5 (24%) 0 (0%) 
  Anorgasmia 1 (5%) 0 (0%) 
  Anorgasmia Male 1 (5%) 0 (0%) 
  Anxiety 3 (14%) 0 (0%) 
  Apathy 1 (5%) 0 (0%) 
  Aphasia 1 (5%) 0 (0%) 
  Appetite Increased 1 (5%) 0 (0%) 
  Appl/Inj/Incision/Insert Site Infection/Inflam 1 (5%) 0 (0%) 
  Appl/Inj/Incision/Insertion Site Pain 1 (5%) 0 (0%) 
  Appl/Inj/Incision/Insertion Site Skin Necrosis 1 (5%) 0 (0%) 
  Arrhythmia 2 (10%) 0 (0%) 
  Arthralgia 6 (29%) 0 (0%) 
  Arthritis 5 (24%) 0 (0%) 
  Arthritis Aggravated 1 (5%) 0 (0%) 
  Arthrosis 4 (19%) 0 (0%) 
  Asthma 3 (14%) 0 (0%) 
  Atrial Fibrillation 1 (5%) 0 (0%) 
  Back Pain 6 (29%) 0 (0%) 
  Bladder Carcinoma 1 (5%) 0 (0%) 
  Blepharitis 1 (5%) 0 (0%) 
  Blood In Stool 1 (5%) 0 (0%) 
  Body Odor 1 (5%) 0 (0%) 
  Bone Disorder 1 (5%) 0 (0%) 
  Bone Fracture Accidental 1 (5%) 0 (0%) 
  Bone Pain 1 (5%) 0 (0%) 
  Breast Neoplasm 2 (10%) 0 (0%) 
  Breast Neoplasm Female 1 (5%) 0 (0%) 




  Breast Pain Female 1 (5%) 0 (0%) 
  Bronchitis 5 (24%) 0 (0%) 
  Bronchospasm Aggravated 1 (5%) 0 (0%) 
  Bruise 1 (5%) 0 (0%) 
  Bun Increased 2 (10%) 0 (0%) 
  Bursitis 1 (5%) 0 (0%) 
  Carcinoma Of Lung 1 (5%) 0 (0%) 
  Cardiac Arrest 1 (5%) 0 (0%) 
  Cardiac Failure 1 (5%) 0 (0%) 
  Cardiovascular Disorder 2 (10%) 0 (0%) 
  Cataract Specified 1 (5%) 0 (0%) 
  Cellulitis 3 (14%) 0 (0%) 
  Cellulitis, Other Than Injection Site 1 (5%) 0 (0%) 
  Cerebrovascular Accident 2 (10%) 0 (0%) 
  Cerebrovascular Disorder 1 (5%) 0 (0%) 
  Cheilitis 1 (5%) 0 (0%) 
  Chest Pain 5 (24%) 0 (0%) 
  Chills 3 (14%) 0 (0%) 
  Chills And Fever 1 (5%) 0 (0%) 
  Cholecystitis 1 (5%) 0 (0%) 
  Cholelithiasis 1 (5%) 0 (0%) 
  Chronic Lymphocytic Leukemia 1 (5%) 0 (0%) 
  Circumoral Paresthesia 2 (10%) 0 (0%) 
  Colitis 3 (14%) 0 (0%) 
  Congenital Anomaly 1 (5%) 0 (0%) 
  Congestive Heart Failure 3 (14%) 0 (0%) 
  Conjunctivitis 5 (24%) 0 (0%) 
  Contact Dermatitis 1 (5%) 0 (0%) 
  Coordination Abnormal 1 (5%) 0 (0%) 
  Coronary Artery Disorder 1 (5%) 0 (0%) 
  Coronary Occlusion 1 (5%) 0 (0%) 
  Cough Increased 5 (24%) 0 (0%) 
  Coughing 1 (5%) 0 (0%) 
  Creatinine Blood Increased 1 (5%) 0 (0%) 
  Creatinine Increased 1 (5%) 0 (0%) 
  Cyst 2 (10%) 0 (0%) 
  Cystitis 1 (5%) 0 (0%) 
  Deafness 2 (10%) 0 (0%) 
  Deep Thrombophlebitis 1 (5%) 0 (0%) 
  Depersonalization 3 (14%) 0 (0%) 
  Depression 5 (24%) 0 (0%) 
  Dermatitis 1 (5%) 0 (0%) 
  Dermatitis Contact 1 (5%) 0 (0%) 
  Dermatitis Fungal 1 (5%) 0 (0%) 
  Diabetes Mellitus 3 (14%) 0 (0%) 
  Diabetes Mellitus Aggravated 1 (5%) 0 (0%) 
  Diplopia 5 (24%) 0 (0%) 
  Diverticulitis 1 (5%) 0 (0%) 




  Dry Eyes 1 (5%) 0 (0%) 
  Dry Skin 3 (14%) 0 (0%) 
  Duodenal Ulcer 1 (5%) 0 (0%) 
  Dysarthria 1 (5%) 0 (0%) 
  Dyspepsia 6 (29%) 0 (0%) 
  Dysphonia 1 (5%) 0 (0%) 
  Dyspnea 6 (29%) 0 (0%) 
  Dysuria 2 (10%) 0 (0%) 
  Ear Disorder 2 (10%) 0 (0%) 
  Ear Pain 4 (19%) 0 (0%) 
  Earache 1 (5%) 0 (0%) 
  Ecchymosis 5 (24%) 0 (0%) 
  Eczema 1 (5%) 0 (0%) 
  Edema 4 (19%) 0 (0%) 
  Edema Generalized 1 (5%) 0 (0%) 
  Emotional Lability 3 (14%) 0 (0%) 
  Encephalitis 1 (5%) 0 (0%) 
  Encephalopathy 1 (5%) 0 (0%) 
  Enteritis 1 (5%) 0 (0%) 
  Epistaxis 2 (10%) 0 (0%) 
  Eructation 1 (5%) 0 (0%) 
  Esophageal Ulcer 1 (5%) 0 (0%) 
  Esophageal Ulceration 1 (5%) 0 (0%) 
  Euphoria 1 (5%) 0 (0%) 
  Event Unevaluable 1 (5%) 0 (0%) 
  Extrapyramidal Syndrome 1 (5%) 0 (0%) 
  Eye Disorder 4 (19%) 0 (0%) 
  Eye Hemorrhage 1 (5%) 0 (0%) 
  Eye Pain 4 (19%) 0 (0%) 
  Face Edema 4 (19%) 0 (0%) 
  Facial Paralysis 1 (5%) 0 (0%) 
  Fecal Impaction 1 (5%) 0 (0%) 
  Fecal Incontinence 1 (5%) 0 (0%) 
  Fever 3 (14%) 0 (0%) 
  Fibrillation Atrial 1 (5%) 0 (0%) 
  Flank Pain 1 (5%) 0 (0%) 
  Flatulence 5 (24%) 0 (0%) 
  Flushing 1 (5%) 0 (0%) 
  Fungal Dermatitis 2 (10%) 0 (0%) 
  Furunculosis 2 (10%) 0 (0%) 
  Gastric Dilatation 1 (5%) 0 (0%) 
  Gastritis 2 (10%) 0 (0%) 
  Gastroenteritis 3 (14%) 0 (0%) 
  Gastroesophageal Reflux 1 (5%) 0 (0%) 
  Gastrointestinal Disorder 5 (24%) 0 (0%) 
  Generalized Edema 3 (14%) 0 (0%) 
  Gingival Bleeding 1 (5%) 0 (0%) 
  Gingivitis 2 (10%) 0 (0%) 




  Gout 2 (10%) 0 (0%) 
  Gum Hemorrhage 1 (5%) 0 (0%) 
  Gynecomastia 1 (5%) 0 (0%) 
  Hair Disorder 1 (5%) 0 (0%) 
  Hearing Decreased 1 (5%) 0 (0%) 
  Heart Arrest 1 (5%) 0 (0%) 
  Heart Failure 2 (10%) 0 (0%) 
  Hematuria 1 (5%) 0 (0%) 
  Hemoptysis 3 (14%) 0 (0%) 
  Hemorrhage 1 (5%) 0 (0%) 
  Hepatic Enzymes Increased 1 (5%) 0 (0%) 
  Hepatic Function Abnormal 1 (5%) 0 (0%) 
  Hepatitis Infectious 1 (5%) 0 (0%) 
  Hernia 2 (10%) 0 (0%) 
  Herpes Simplex 4 (19%) 0 (0%) 
  Herpes Zoster 3 (14%) 0 (0%) 
  Hiccup 1 (5%) 0 (0%) 
  Hot Flushes 1 (5%) 0 (0%) 
  Hypercholesterolemia 1 (5%) 0 (0%) 
  Hyperesthesia 1 (5%) 0 (0%) 
  Hyperglycemia 6 (29%) 0 (0%) 
  Hyperlipidemia 1 (5%) 0 (0%) 
  Hyperostosis 1 (5%) 0 (0%) 
  Hypertension 4 (19%) 0 (0%) 
  Hypertension Aggravated 1 (5%) 0 (0%) 
  Hypertonia 3 (14%) 0 (0%) 
  Hypesthesia 6 (29%) 0 (0%) 
  Hypoacusis 1 (5%) 0 (0%) 
  Hypoesthesia 1 (5%) 0 (0%) 
  Hypoglycemia 3 (14%) 0 (0%) 
  Hypokinesia 1 (5%) 0 (0%) 
  Hypothyroidism 1 (5%) 0 (0%) 
  Ileitis 1 (5%) 0 (0%) 
  Impotence 4 (19%) 0 (0%) 
  Incoordination 5 (24%) 0 (0%) 
  Increased Appetite 4 (19%) 0 (0%) 
  Increased Capillary Fragility 1 (5%) 0 (0%) 
  Infection Bacterial 1 (5%) 0 (0%) 
  Infection Tbc 1 (5%) 0 (0%) 
  Influenza-Like Symptoms 1 (5%) 0 (0%) 
  Insomnia 6 (29%) 0 (0%) 
  Intestinal Obstruction 1 (5%) 0 (0%) 
  Intestinal Ulcer 1 (5%) 0 (0%) 
  Irritability 1 (5%) 0 (0%) 
  Irritable Bowel Syndrome 1 (5%) 0 (0%) 
  Joint Disorder 2 (10%) 0 (0%) 
  Kidney Calculus 2 (10%) 0 (0%) 
  Kidney Pain 1 (5%) 0 (0%) 




  Labile Blood Pressure 1 (5%) 0 (0%) 
  Lacrimation Disorder 1 (5%) 0 (0%) 
  Lactic Dehydrogenase Increased 2 (10%) 0 (0%) 
  LDH Increased 1 (5%) 0 (0%) 
  Leg Cramps 5 (24%) 0 (0%) 
  Libido Decreased 2 (10%) 0 (0%) 
  Libido Increased 1 (5%) 0 (0%) 
  Liver Fatty 1 (5%) 0 (0%) 
  Liver Fatty Deposit 1 (5%) 0 (0%) 
  Liver Function Tests Abnormal 3 (14%) 0 (0%) 
  Lung Disorder 2 (10%) 0 (0%) 
  Lymphadenopathy 2 (10%) 0 (0%) 
  Lymphadenopathy Cervical 1 (5%) 0 (0%) 
  Maculopapular Rash 1 (5%) 0 (0%) 
  Malabsorption Syndrome 1 (5%) 0 (0%) 
  Malaise 3 (14%) 0 (0%) 
  Melena 1 (5%) 0 (0%) 
  Micturition Disorder 1 (5%) 0 (0%) 
  Micturition Frequency 1 (5%) 0 (0%) 
  Migraine 3 (14%) 0 (0%) 
  Migraine Aggravated 1 (5%) 0 (0%) 
  Motor Vehicle Accident 1 (5%) 0 (0%) 
  Mouth Dry 1 (5%) 0 (0%) 
  Mouth Ulceration 2 (10%) 0 (0%) 
  Movement Disorder 2 (10%) 0 (0%) 
  Mucous Membrane Disorder 1 (5%) 0 (0%) 
  Muscle Contractions Involuntary 1 (5%) 0 (0%) 
  Muscle Cramps 1 (5%) 0 (0%) 
  Muscle Weakness 1 (5%) 0 (0%) 
  Muscular Hypertonia 1 (5%) 0 (0%) 
  Myalgia 6 (29%) 0 (0%) 
  Myasthenia 5 (24%) 0 (0%) 
  Myocardial Infarct 2 (10%) 0 (0%) 
  Myocardial Ischemia 1 (5%) 0 (0%) 
  Myoclonus 1 (5%) 0 (0%) 
  Myopia 1 (5%) 0 (0%) 
  Nail Disorder 1 (5%) 0 (0%) 
  Nausea Vomiting And Diarrhea 1 (5%) 0 (0%) 
  Neck Pain 4 (19%) 0 (0%) 
  Neoplasm 2 (10%) 0 (0%) 
  Nephritis 1 (5%) 0 (0%) 
  Nervousness 6 (29%) 0 (0%) 
  Neuralgia 2 (10%) 0 (0%) 
  Neuropathy 4 (19%) 0 (0%) 
  Nocturia 3 (14%) 0 (0%) 
  Nystagmus 1 (5%) 0 (0%) 
  Oral Moniliasis 3 (14%) 0 (0%) 
  Other And Unspecified Neoplasms 1 (5%) 0 (0%) 




  Other Sexual Dysfunction Male 1 (5%) 0 (0%) 
  Otitis Media 6 (29%) 0 (0%) 
  Palpitation 4 (19%) 0 (0%) 
  Pancreatitis 2 (10%) 0 (0%) 
  Paralysis 1 (5%) 0 (0%) 
  Paranoid Reaction 1 (5%) 0 (0%) 
  Paresthesia 4 (19%) 0 (0%) 
  Pelvic Pain 1 (5%) 0 (0%) 
  Penis Disorder 2 (10%) 0 (0%) 
  Periodontal Abscess 2 (10%) 0 (0%) 
  Peripheral Vascular Disorder 2 (10%) 0 (0%) 
  Pharyngitis 6 (29%) 0 (0%) 
  Phlebitis 1 (5%) 0 (0%) 
  Photophobia 1 (5%) 0 (0%) 
  Pneumonia 3 (14%) 0 (0%) 
  Polyuria 3 (14%) 0 (0%) 
  Prostatic Disorder 1 (5%) 0 (0%) 
  Prothrombin Decreased 1 (5%) 0 (0%) 
  Pruritus 6 (29%) 0 (0%) 
  Psoriasis 2 (10%) 0 (0%) 
  Psoriasis Aggravated 1 (5%) 0 (0%) 
  Purpura 1 (5%) 0 (0%) 
  Pyelonephritis 2 (10%) 0 (0%) 
  Pyuria 1 (5%) 0 (0%) 
  Rash 5 (24%) 0 (0%) 
  Rash Erythematous 1 (5%) 0 (0%) 
  Reaction Unevaluable 1 (5%) 0 (0%) 
  Rectal Disorder 2 (10%) 0 (0%) 
  Rectal Hemorrhage 2 (10%) 0 (0%) 
  Reflexes Decreased 1 (5%) 0 (0%) 
  Refraction Disorder 1 (5%) 0 (0%) 
  Renal Calculus 1 (5%) 0 (0%) 
  Renal Pain 1 (5%) 0 (0%) 
  Respiratory Disorder 1 (5%) 0 (0%) 
  Respiratory System 1 (5%) 0 (0%) 
  Respiratory Tract Infection 1 (5%) 0 (0%) 
  Retinal Disorder 1 (5%) 0 (0%) 
  Retinal Hemorrhage 1 (5%) 0 (0%) 
  Retinal Vascular Disorder 1 (5%) 0 (0%) 
  Retinal Vein Thrombosis 1 (5%) 0 (0%) 
  Rheumatoid Arthritis 1 (5%) 0 (0%) 
  Rhinitis 5 (24%) 0 (0%) 
  Salivary Duct Obstruction 1 (5%) 0 (0%) 
  Scrotal Edema 1 (5%) 0 (0%) 
  Sepsis 2 (10%) 0 (0%) 
  SGOT Increased 1 (5%) 0 (0%) 
  SGPT Increased 1 (5%) 0 (0%) 
  Sialolithiasis 1 (5%) 0 (0%) 




  Skeletal Pain 1 (5%) 0 (0%) 
  Skin Benign Neoplasm 2 (10%) 0 (0%) 
  Skin Carcinoma 1 (5%) 0 (0%) 
  Skin Cold Clammy 1 (5%) 0 (0%) 
  Skin Discoloration 2 (10%) 0 (0%) 
  Skin Disorder 4 (19%) 0 (0%) 
  Skin Dry 1 (5%) 0 (0%) 
  Skin Ulcer 3 (14%) 0 (0%) 
  Skin Ulceration 1 (5%) 0 (0%) 
  Speech Disorder 4 (19%) 0 (0%) 
  Stomach Atony 1 (5%) 0 (0%) 
  Stomatitis 1 (5%) 0 (0%) 
  Stools Loose 1 (5%) 0 (0%) 
  Stupor 2 (10%) 0 (0%) 
  Sweating 6 (29%) 0 (0%) 
  Sweating Increased 1 (5%) 0 (0%) 
  Syncope 4 (19%) 0 (0%) 
  Synovitis 1 (5%) 0 (0%) 
  Tachycardia 2 (10%) 0 (0%) 
  Taste Loss 1 (5%) 0 (0%) 
  Taste Perversion 3 (14%) 0 (0%) 
  Tendinitis 1 (5%) 0 (0%) 
  Tendinous Contracture 1 (5%) 0 (0%) 
  Tenosynovitis 2 (10%) 0 (0%) 
  Thinking Abnormal 5 (24%) 0 (0%) 
  Thirst 5 (24%) 0 (0%) 
  Thrombocytopenia 1 (5%) 0 (0%) 
  Thrombophlebitis 1 (5%) 0 (0%) 
  Thrombophlebitis Leg Deep 1 (5%) 0 (0%) 
  Thrombosis 2 (10%) 0 (0%) 
  Thrombosis Coronary 1 (5%) 0 (0%) 
  Tinnitus 3 (14%) 0 (0%) 
  Tongue Disorder 1 (5%) 0 (0%) 
  Tooth Ache 1 (5%) 0 (0%) 
  Tooth Disorder 4 (19%) 0 (0%) 
  Tremor 4 (19%) 0 (0%) 
  Twitching 4 (19%) 0 (0%) 
  Urethral Pain 1 (5%) 0 (0%) 
  Urethral/Ureteral Disorder 1 (5%) 0 (0%) 
  Urinary Frequency 5 (24%) 0 (0%) 
  Urinary Incontinence 3 (14%) 0 (0%) 
  Urinary Retention 1 (5%) 0 (0%) 
  Urinary Tract Disorder 1 (5%) 0 (0%) 
  Urinary Tract Infection 5 (24%) 0 (0%) 
  Urinary Urgency 1 (5%) 0 (0%) 
  Urine Abnormality 1 (5%) 0 (0%) 
  Urticaria 1 (5%) 0 (0%) 
  Vascular Disorder 1 (5%) 0 (0%) 




  Verruca 1 (5%) 0 (0%) 
  Vesiculobullous Rash 4 (19%) 0 (0%) 
  Vestibular Disorder 1 (5%) 0 (0%) 
  Voice Alteration 2 (10%) 0 (0%) 
  Vomiting 6 (29%) 0 (0%) 
  Weight Decrease 1 (5%) 0 (0%) 
  Weight Gain 5 (24%) 0 (0%) 
  Weight Loss 2 (10%) 0 (0%) 
  Worsening Heart Failure 1 (5%) 0 (0%) 
  Xerophthalmia 1 (5%) 0 (0%) 
Named serious adverse events  
  Cardiac Failure Congestion 1 (5%) 1 (5%) 
  Cellulitis 2 (10%) 1 (5%) 
  Hematuria 1 (5%) 1 (5%) 
  Left Arm Fracture 1 (5%) 1 (5%) 
  Myocardial Infarction 1 (5%) 1 (5%) 
  Osteochondrosis 1 (5%) 1 (5%) 
  Pancoast Tumor 1 (5%) 1 (5%) 
  Pancreatitis Chronic 1 (5%) 1 (5%) 
  Thrombophlebitis 1 (5%) 1 (5%) 
  Abscess 1 (5%) 0 (0%) 
  Accidental Injury 4 (19%) 0 (0%) 
  Alkaline Phosphatase Increased 1 (5%) 0 (0%) 
  Angina Pectoris 2 (10%) 0 (0%) 
  Arthritis 1 (5%) 0 (0%) 
  Arthrosis 1 (5%) 0 (0%) 
  Asthenia 1 (5%) 0 (0%) 
  Back Pain 1 (5%) 0 (0%) 
  Bladder Carcinoma 1 (5%) 0 (0%) 
  Bone Disorder 1 (5%) 0 (0%) 
  Bone Fracture Accidental 1 (5%) 0 (0%) 
  Carcinoma Of Lung 1 (5%) 0 (0%) 
  Cardiac Arrest 1 (5%) 0 (0%) 
  Cardiac Failure 1 (5%) 0 (0%) 
  Cerebrovascular Accident 1 (5%) 0 (0%) 
  Cerebrovascular Disorder 1 (5%) 0 (0%) 
  Chest Pain 3 (14%) 0 (0%) 
  Cholecystitis 1 (5%) 0 (0%) 
  Cholelithiasis 1 (5%) 0 (0%) 
  Chronic Lymphocytic Leukemia 1 (5%) 0 (0%) 
  Congestive Heart Failure 2 (10%) 0 (0%) 
  Constipation 1 (5%) 0 (0%) 
  Coronary Artery Disorder 1 (5%) 0 (0%) 
  Death 1 (5%) 0 (0%) 
  Depression 2 (10%) 0 (0%) 
  Dizziness 1 (5%) 0 (0%) 
  Dyspnea 1 (5%) 0 (0%) 
  Encephalopathy 1 (5%) 0 (0%) 





  Glucose Tolerance Decreased 1 (5%) 0 (0%) 
  Headache 1 (5%) 0 (0%) 
  Hemoptysis 1 (5%) 0 (0%) 
  Hyperglycemia 1 (5%) 0 (0%) 
  Hypertension 1 (5%) 0 (0%) 
  Infection 1 (5%) 0 (0%) 
  Infection Tbc 1 (5%) 0 (0%) 
  Intestinal Obstruction 1 (5%) 0 (0%) 
  Maculopapular Rash 1 (5%) 0 (0%) 
  Malabsorption Syndrome 1 (5%) 0 (0%) 
  Motor Vehicle Accident 1 (5%) 0 (0%) 
  Myasthenia 1 (5%) 0 (0%) 
  Myocardial Infarct 2 (10%) 0 (0%) 
  Myocardial Ischemia 1 (5%) 0 (0%) 
  Nausea 1 (5%) 0 (0%) 
  Pancreatitis 2 (10%) 0 (0%) 
  Pneumonia 3 (14%) 0 (0%) 
  Pyelonephritis 1 (5%) 0 (0%) 
  Rectal Disorder 1 (5%) 0 (0%) 
  Retinal Vein Thrombosis 1 (5%) 0 (0%) 
  Skin Carcinoma 1 (5%) 0 (0%) 
  Skin Ulcer 1 (5%) 0 (0%) 
  Stomach Atony 1 (5%) 0 (0%) 
  Syncope 4 (19%) 0 (0%) 
  Thrombophlebitis Leg Deep 1 (5%) 0 (0%) 
  Thrombosis 1 (5%) 0 (0%) 
  Thrombosis Coronary 1 (5%) 0 (0%) 
  Vertigo 1 (5%) 0 (0%) 
  Vomiting 2 (10%) 0 (0%) 




Appendix Table 2-3. Quetiapine trials with data that could be included in a meta-
analysis, by whether the data source is public  
Appendix Table 2-3 Legend: For example, when including data from any source, 3/7 (43%) trials reported 
meta-analyzable results for the number of participants who experienced anxiety. When including only 
data from public sources, 1/7 (14%) trials reported meta-analyzable results for the number of participants 
who experienced anxiety. 
The first section of the table includes the number of participants experiencing any AE(s) and the number 
of participants experiencing any serious AE(s).  
The second section of the table includes specific adverse events (in alphabetical order) for which meta-
analyzable data were reported in a public source for at least one trial, followed by specific adverse events 
(in alphabetical order) for which meta-analyzable data were not reported in any public sources.  
The third section of the table includes specific serious adverse events (in alphabetical order) for which 
meta-analyzable data were reported in a public source for at least one trial, followed by specific serious 
adverse events (in alphabetical order) for which meta-analyzable data were not reported in any public 
sources. 
  Quetiapine for bipolar depression (N=7 trials) 
  
Trials with meta-analyzable 
data across all sources 
No. (%) 
Trials with meta-analyzable 
data across public sources 
No. (%) 
Aggregated adverse events   
  No. participants experiencing ≥1 AE 6 (86%) 3 (43%) 
  No. participants experiencing ≥1 serious AE 5 (71%) 4 (57%) 
Named adverse events   
  Anxiety 3 (43%) 1 (14%) 
  Appetite Decrease 2 (29%) 1 (14%) 
  Appetite Increase 4 (57%) 3 (43%) 
  Constipation 5 (71%) 5 (71%) 
  Diarrhea 4 (57%) 3 (43%) 
  Dizziness 6 (86%) 6 (86%) 
  Dry Mouth 6 (86%) 6 (86%) 
  Dyspepsia 4 (57%) 2 (29%) 
  Fatigue 4 (57%) 4 (57%) 
  Headache 6 (86%) 6 (86%) 
  Hypomania 3 (43%) 1 (14%) 
  Insomnia 5 (71%) 3 (43%) 
  Light-Headed 1 (14%) 1 (14%) 
  Nasopharyngitis 3 (43%) 1 (14%) 
  Nausea 6 (86%) 6 (86%) 
  Sedation 6 (86%) 6 (86%) 
  Somnolence 5 (71%) 5 (71%) 
  Stomach Upset 1 (14%) 1 (14%) 
  Tremor 3 (43%) 1 (14%) 
  Upper Respiratory Tract Infection 2 (29%) 1 (14%) 
  Weight Gain 1 (14%) 1 (14%) 
  Abdominal Discomfort 2 (29%) 0 (0%) 




  Abdominal Pain 1 (14%) 0 (0%) 
  Abdominal Pain Lower 2 (29%) 0 (0%) 
  Abdominal Pain NOS 1 (14%) 0 (0%) 
  Abdominal Pain Upper 2 (29%) 0 (0%) 
  Abdominal Tenderness 1 (14%) 0 (0%) 
  Abnormal Dreams 2 (29%) 0 (0%) 
  Accidental Overdose 2 (29%) 0 (0%) 
  Acne 1 (14%) 0 (0%) 
  Acne NOS 1 (14%) 0 (0%) 
  Acute Myocardial Infarction 1 (14%) 0 (0%) 
  Acute Psychosis 1 (14%) 0 (0%) 
  Adnexa Uteri Pain 1 (14%) 0 (0%) 
  Aggression 1 (14%) 0 (0%) 
  Agitation 2 (29%) 0 (0%) 
  Akathisia 2 (29%) 0 (0%) 
  Alcohol Intolerance 1 (14%) 0 (0%) 
  Alopecia 2 (29%) 0 (0%) 
  Altered Visual Depth Perception 2 (29%) 0 (0%) 
  Amnesia 2 (29%) 0 (0%) 
  Anemia 1 (14%) 0 (0%) 
  Anger 2 (29%) 0 (0%) 
  Anorexia 1 (14%) 0 (0%) 
  Anorgasmia 1 (14%) 0 (0%) 
  Aphasia 1 (14%) 0 (0%) 
  Aphthous Stomatitis 1 (14%) 0 (0%) 
  Appetite Decrease NOS 1 (14%) 0 (0%) 
  Appetite Increase NOS 1 (14%) 0 (0%) 
  Aptyalism 1 (14%) 0 (0%) 
  Arthralgia 2 (29%) 0 (0%) 
  Arthritis NOS 1 (14%) 0 (0%) 
  Arthropod Bite 2 (29%) 0 (0%) 
  Arthropod Sting 1 (14%) 0 (0%) 
  Asthenia 2 (29%) 0 (0%) 
  Asthma NOS 1 (14%) 0 (0%) 
  Astigmatism 1 (14%) 0 (0%) 
  Ataxia 2 (29%) 0 (0%) 
  Atrioventricular Block First Degree 1 (14%) 0 (0%) 
  Back Injury 1 (14%) 0 (0%) 
  Back Injury NOS 1 (14%) 0 (0%) 
  Back Pain 2 (29%) 0 (0%) 
  Balance Disorder 1 (14%) 0 (0%) 
  Balance Impaired NOS 1 (14%) 0 (0%) 
  Bipolar Disorder 1 (14%) 0 (0%) 
  Bipolar I Disorder 2 (29%) 0 (0%) 
  Bladder Disorder NOS 1 (14%) 0 (0%) 
  Blepharitis 1 (14%) 0 (0%) 
  Blepharospasm 1 (14%) 0 (0%) 
  Blood In Stool 1 (14%) 0 (0%) 




  Blood Pressure Systolic Increased 1 (14%) 0 (0%) 
  Blood Triglycerides Increased 1 (14%) 0 (0%) 
  Blood Urine 1 (14%) 0 (0%) 
  Blunted Affect 1 (14%) 0 (0%) 
  Body Temperature Increased 1 (14%) 0 (0%) 
  Bradycardia 1 (14%) 0 (0%) 
  Bradyphrenia 1 (14%) 0 (0%) 
  Breast Cyst 1 (14%) 0 (0%) 
  Breast Tenderness 1 (14%) 0 (0%) 
  Bronchitis 1 (14%) 0 (0%) 
  Bronchitis NOS 1 (14%) 0 (0%) 
  Bronchospasm NOS 1 (14%) 0 (0%) 
  Bruxism 2 (29%) 0 (0%) 
  Buttock Pain 1 (14%) 0 (0%) 
  Carpal Tunnel Syndrome 1 (14%) 0 (0%) 
  Cerumen Impaction 1 (14%) 0 (0%) 
  Chapped Lips 1 (14%) 0 (0%) 
  Cheilitis 1 (14%) 0 (0%) 
  Chemical Injury 1 (14%) 0 (0%) 
  Chest Discomfort 2 (29%) 0 (0%) 
  Chest Pain 2 (29%) 0 (0%) 
  Chest Tightness 1 (14%) 0 (0%) 
  Chest Wall Pain 2 (29%) 0 (0%) 
  Chills 1 (14%) 0 (0%) 
  Chlamydial Infection 1 (14%) 0 (0%) 
  Choking Sensation 1 (14%) 0 (0%) 
  Cholecystitis NOS 1 (14%) 0 (0%) 
  Chronic Lymphocytic Leukemia NOS 1 (14%) 0 (0%) 
  Chronic Obstructive Airways Disease 1 (14%) 0 (0%) 
  Cognitive Disorder 1 (14%) 0 (0%) 
  Confusional State 2 (29%) 0 (0%) 
  Conjunctival Hyperemia 1 (14%) 0 (0%) 
  Conjunctivitis Infective 1 (14%) 0 (0%) 
  Constricted Affect 1 (14%) 0 (0%) 
  Contusion 2 (29%) 0 (0%) 
  Conversion Disorder 1 (14%) 0 (0%) 
  Convulsion 1 (14%) 0 (0%) 
  Convulsions NOS 1 (14%) 0 (0%) 
  Coordination Abnormal 1 (14%) 0 (0%) 
  Coordination Abnormal NOS 1 (14%) 0 (0%) 
  Corneal Abrasion 1 (14%) 0 (0%) 
  Cough 2 (29%) 0 (0%) 
  Decreased Immune Responsiveness 1 (14%) 0 (0%) 
  Deep Vein Thrombosis 1 (14%) 0 (0%) 
  Delusion NOS 1 (14%) 0 (0%) 
  Depression 2 (29%) 0 (0%) 
  Derealization 1 (14%) 0 (0%) 
  Dermatitis Allergic 1 (14%) 0 (0%) 




  Dermatitis Exfoliative NOS 1 (14%) 0 (0%) 
  Diarrhea NOS 1 (14%) 0 (0%) 
  Difficulty In Walking 1 (14%) 0 (0%) 
  Diplopia 1 (14%) 0 (0%) 
  Disorientation 2 (29%) 0 (0%) 
  Dissociation 1 (14%) 0 (0%) 
  Dissociative Disorder NOS 1 (14%) 0 (0%) 
  Disturbance In Attention 2 (29%) 0 (0%) 
  Dizziness Postural 2 (29%) 0 (0%) 
  Drug Abuser NOS 1 (14%) 0 (0%) 
  Drug Hypersensitivity 1 (14%) 0 (0%) 
  Drug Withdrawal Syndrome 1 (14%) 0 (0%) 
  Dry Eye 1 (14%) 0 (0%) 
  Dry Eye NOS 1 (14%) 0 (0%) 
  Dry Skin 1 (14%) 0 (0%) 
  Dry Throat 1 (14%) 0 (0%) 
  Duodenal Ulcer Hemorrhage 1 (14%) 0 (0%) 
  Dupuytren's Contracture 1 (14%) 0 (0%) 
  Dysarthria 2 (29%) 0 (0%) 
  Dysgeusia 2 (29%) 0 (0%) 
  Dyskinesia 2 (29%) 0 (0%) 
  Dysmenorrhea 2 (29%) 0 (0%) 
  Dysphagia 2 (29%) 0 (0%) 
  Dysphemia 1 (14%) 0 (0%) 
  Dyspnea 2 (29%) 0 (0%) 
  Dystonia 2 (29%) 0 (0%) 
  Dysuria 2 (29%) 0 (0%) 
  Ear Congestion 2 (29%) 0 (0%) 
  Ear Discomfort 1 (14%) 0 (0%) 
  Ear Infection 1 (14%) 0 (0%) 
  Ear Infection NOS 1 (14%) 0 (0%) 
  Ear Infection Viral NOS 1 (14%) 0 (0%) 
  Ear Pain 2 (29%) 0 (0%) 
  Ear Pruritus 1 (14%) 0 (0%) 
  Ecchymosis 1 (14%) 0 (0%) 
  Ectopic Pregnancy 1 (14%) 0 (0%) 
  Edema Peripheral 2 (29%) 0 (0%) 
  Ejaculation Delayed 1 (14%) 0 (0%) 
  Elevated Mood 1 (14%) 0 (0%) 
  Enuresis 1 (14%) 0 (0%) 
  Epistaxis 2 (29%) 0 (0%) 
  Erectile Dysfunction 1 (14%) 0 (0%) 
  Erectile Dysfunction NOS 1 (14%) 0 (0%) 
  Eructation 1 (14%) 0 (0%) 
  Erythema 1 (14%) 0 (0%) 
  Esophageal Spasm 1 (14%) 0 (0%) 
  Euphoric Mood 1 (14%) 0 (0%) 
  Excoriation 1 (14%) 0 (0%) 




  Eye Pain 1 (14%) 0 (0%) 
  Eye Redness 1 (14%) 0 (0%) 
  Eye Swelling 1 (14%) 0 (0%) 
  Eyelids Pruritus 1 (14%) 0 (0%) 
  Facial Pain 1 (14%) 0 (0%) 
  Factor Ii Deficiency 1 (14%) 0 (0%) 
  Feces Hard 1 (14%) 0 (0%) 
  Feeling Abnormal 1 (14%) 0 (0%) 
  Feeling Cold 1 (14%) 0 (0%) 
  Feeling Hot 2 (29%) 0 (0%) 
  Feeling Hot And Cold 1 (14%) 0 (0%) 
  Feeling Jittery 2 (29%) 0 (0%) 
  Fibula Fracture 1 (14%) 0 (0%) 
  Flank Pain 2 (29%) 0 (0%) 
  Flat Affect 2 (29%) 0 (0%) 
  Flatulence 2 (29%) 0 (0%) 
  Fluid Retention 1 (14%) 0 (0%) 
  Flushing 2 (29%) 0 (0%) 
  Food Craving 2 (29%) 0 (0%) 
  Food Poisoning 1 (14%) 0 (0%) 
  Food Poisoning NOS 1 (14%) 0 (0%) 
  Foot Fracture 1 (14%) 0 (0%) 
  Fractured Coccyx 1 (14%) 0 (0%) 
  Frequent Bowel Movements 1 (14%) 0 (0%) 
  Fungal Infection NOS 1 (14%) 0 (0%) 
  Gait Abnormal 1 (14%) 0 (0%) 
  Gait Disturbance 1 (14%) 0 (0%) 
  Gastritis 1 (14%) 0 (0%) 
  Gastroenteritis 1 (14%) 0 (0%) 
  Gastroenteritis Viral 1 (14%) 0 (0%) 
  Gastroenteritis Viral NOS 1 (14%) 0 (0%) 
  Gastroesophageal Reflux Disease 2 (29%) 0 (0%) 
  Gastrointestinal Pain NOS 1 (14%) 0 (0%) 
  Gingival Infection 1 (14%) 0 (0%) 
  Gingival Pain 2 (29%) 0 (0%) 
  Glossodynia 2 (29%) 0 (0%) 
  Gout 1 (14%) 0 (0%) 
  Groin Pain 1 (14%) 0 (0%) 
  Haemorrhoids 1 (14%) 0 (0%) 
  Hallucination 1 (14%) 0 (0%) 
  Hallucination, Auditory 2 (29%) 0 (0%) 
  Hallucination, Visual 2 (29%) 0 (0%) 
  Hand Fracture 1 (14%) 0 (0%) 
  Hangover 1 (14%) 0 (0%) 
  Heart Rate Increased 1 (14%) 0 (0%) 
  Heart Rate Irregular 1 (14%) 0 (0%) 
  Hematoma NOS 1 (14%) 0 (0%) 
  Hemiparesis 1 (14%) 0 (0%) 




  Hernia NOS 1 (14%) 0 (0%) 
  Herpes Simplex 2 (29%) 0 (0%) 
  Hiccups 1 (14%) 0 (0%) 
  Hip Fracture 1 (14%) 0 (0%) 
  Hoarseness 1 (14%) 0 (0%) 
  Hostility 1 (14%) 0 (0%) 
  Hot Flush 1 (14%) 0 (0%) 
  Hyperacusis 1 (14%) 0 (0%) 
  Hyperglycemia 1 (14%) 0 (0%) 
  Hyperhidrosis 1 (14%) 0 (0%) 
  Hyperkeratosis 1 (14%) 0 (0%) 
  Hyperreflexia 1 (14%) 0 (0%) 
  Hypersensitivity 1 (14%) 0 (0%) 
  Hypersensitivity NOS 1 (14%) 0 (0%) 
  Hypersomnia 2 (29%) 0 (0%) 
  Hypertension 1 (14%) 0 (0%) 
  Hypertension NOS 1 (14%) 0 (0%) 
  Hypnagogic Hallucination 1 (14%) 0 (0%) 
  Hypoesthesia 2 (29%) 0 (0%) 
  Hypoesthesia Oral 1 (14%) 0 (0%) 
  Hyporeflexia 1 (14%) 0 (0%) 
  Hypotension NOS 1 (14%) 0 (0%) 
  Hypothyroidism 1 (14%) 0 (0%) 
  Illusion 1 (14%) 0 (0%) 
  Increased Tendency To Bruise 1 (14%) 0 (0%) 
  Infected Insect Bite 1 (14%) 0 (0%) 
  Influenza 2 (29%) 0 (0%) 
  Influenza Like Illness 2 (29%) 0 (0%) 
  Initial Insomnia 1 (14%) 0 (0%) 
  Injury 1 (14%) 0 (0%) 
  Intervertebral Disc Herniation 1 (14%) 0 (0%) 
  Intestinal Obstruction NOS 1 (14%) 0 (0%) 
  Irritability 2 (29%) 0 (0%) 
  Irritable Bowel Syndrome 2 (29%) 0 (0%) 
  Joint Dislocation 1 (14%) 0 (0%) 
  Joint Sprain 2 (29%) 0 (0%) 
  Joint Stiffness 1 (14%) 0 (0%) 
  Joint Swelling 1 (14%) 0 (0%) 
  Kidney Infection NOS 1 (14%) 0 (0%) 
  Lacrimation Increased 1 (14%) 0 (0%) 
  Laryngeal Edema 1 (14%) 0 (0%) 
  Laryngitis NOS 1 (14%) 0 (0%) 
  Lethargy 2 (29%) 0 (0%) 
  Libido Decreased 2 (29%) 0 (0%) 
  Libido Increased 2 (29%) 0 (0%) 
  Limb Discomfort NOS 1 (14%) 0 (0%) 
  Limb Injury NOS 1 (14%) 0 (0%) 
  Localized Infection 1 (14%) 0 (0%) 




  Loose Stools 1 (14%) 0 (0%) 
  Loss Of Libido 2 (29%) 0 (0%) 
  Lymphadenopathy 1 (14%) 0 (0%) 
  Major Depressive Disorder NOS 1 (14%) 0 (0%) 
  Malaise 1 (14%) 0 (0%) 
  Mania 2 (29%) 0 (0%) 
  Memory Impairment 2 (29%) 0 (0%) 
  Menorrhagia 1 (14%) 0 (0%) 
  Menses Delayed 1 (14%) 0 (0%) 
  Menstruation Irregular 2 (29%) 0 (0%) 
  Mental Impairment NOS 1 (14%) 0 (0%) 
  Mental Status Changes 1 (14%) 0 (0%) 
  Micturition Urgency 2 (29%) 0 (0%) 
  Middle Insomnia 1 (14%) 0 (0%) 
  Migraine 1 (14%) 0 (0%) 
  Migraine NOS 1 (14%) 0 (0%) 
  Mitral Valve Prolapse 1 (14%) 0 (0%) 
  Mood Swings 1 (14%) 0 (0%) 
  Mucous Membrane Disorder NOS 1 (14%) 0 (0%) 
  Muscle Contractions Involuntary 1 (14%) 0 (0%) 
  Muscle Cramp 2 (29%) 0 (0%) 
  Muscle Rigidity 1 (14%) 0 (0%) 
  Muscle Spasms 2 (29%) 0 (0%) 
  Muscle Stiffness 1 (14%) 0 (0%) 
  Muscle Strain 2 (29%) 0 (0%) 
  Muscle Tightness 2 (29%) 0 (0%) 
  Muscle Twitching 2 (29%) 0 (0%) 
  Muscle Weakness NOS 1 (14%) 0 (0%) 
  Musculoskeletal Discomfort 1 (14%) 0 (0%) 
  Musculoskeletal Pain 1 (14%) 0 (0%) 
  Musculoskeletal Stiffness 2 (29%) 0 (0%) 
  Myalgia 2 (29%) 0 (0%) 
  Myoclonus 1 (14%) 0 (0%) 
  Nasal Congestion 2 (29%) 0 (0%) 
  Nasal Dryness 2 (29%) 0 (0%) 
  Nasal Edema 1 (14%) 0 (0%) 
  Neck Pain 1 (14%) 0 (0%) 
  Nephrolithiasis 1 (14%) 0 (0%) 
  Nervousness 2 (29%) 0 (0%) 
  Night Sweats 2 (29%) 0 (0%) 
  Nightmare 2 (29%) 0 (0%) 
  Nipple Exudate Bloody 1 (14%) 0 (0%) 
  Nocturia 1 (14%) 0 (0%) 
  Non-Accidental Overdose 1 (14%) 0 (0%) 
  Non-Cardiac Chest Pain 1 (14%) 0 (0%) 
  Obsessive-Compulsive Disorder 2 (29%) 0 (0%) 
  Onychophagia 1 (14%) 0 (0%) 
  Oral Pain 1 (14%) 0 (0%) 




  Osteoarthritis 1 (14%) 0 (0%) 
  Otitis Externa 1 (14%) 0 (0%) 
  Otitis Externa NOS 1 (14%) 0 (0%) 
  Otitis Media NOS 1 (14%) 0 (0%) 
  Pain 1 (14%) 0 (0%) 
  Pain In Extremity 2 (29%) 0 (0%) 
  Pain NOS 1 (14%) 0 (0%) 
  Palpitations 2 (29%) 0 (0%) 
  Pancreatitis NOS 1 (14%) 0 (0%) 
  Panic Attack 2 (29%) 0 (0%) 
  Panic Disorder NOS 1 (14%) 0 (0%) 
  Paranoia 2 (29%) 0 (0%) 
  Paresthesia 2 (29%) 0 (0%) 
  Paresthesia Oral 1 (14%) 0 (0%) 
  Periarthritis 1 (14%) 0 (0%) 
  Periorbital Hematoma 1 (14%) 0 (0%) 
  Pharyngeal Erythema 1 (14%) 0 (0%) 
  Pharyngitis 1 (14%) 0 (0%) 
  Pharyngitis Streptococcal 2 (29%) 0 (0%) 
  Pharyngolaryngeal Pain 2 (29%) 0 (0%) 
  Photophobia 2 (29%) 0 (0%) 
  Photopsia 1 (14%) 0 (0%) 
  Photosensitivity Reaction 1 (14%) 0 (0%) 
  Pitting Edema 1 (14%) 0 (0%) 
  Pneumonia 1 (14%) 0 (0%) 
  Pollakiuria 2 (29%) 0 (0%) 
  Polymenorrhea 1 (14%) 0 (0%) 
  Polymyalgia 1 (14%) 0 (0%) 
  Post Procedural Complication 1 (14%) 0 (0%) 
  Post Procedural Pain 2 (29%) 0 (0%) 
  Productive Cough 1 (14%) 0 (0%) 
  Prostate Infection 1 (14%) 0 (0%) 
  Prostatitis 1 (14%) 0 (0%) 
  Pruritus 2 (29%) 0 (0%) 
  Pruritus Generalized 1 (14%) 0 (0%) 
  Psychomotor Hyperactivity 1 (14%) 0 (0%) 
  Psychomotor Retardation 1 (14%) 0 (0%) 
  Pulmonary Congestion 1 (14%) 0 (0%) 
  Pyrexia 2 (29%) 0 (0%) 
  Rash 1 (14%) 0 (0%) 
  Rash NOS 1 (14%) 0 (0%) 
  Rash Pruritic 1 (14%) 0 (0%) 
  Respiratory Tract Congestion 1 (14%) 0 (0%) 
  Respiratory Tract Infection 1 (14%) 0 (0%) 
  Restless Legs Syndrome 2 (29%) 0 (0%) 
  Restlessness 2 (29%) 0 (0%) 
  Retching 1 (14%) 0 (0%) 
  Rhinitis 1 (14%) 0 (0%) 




  Rib Fracture 1 (14%) 0 (0%) 
  Rigors 1 (14%) 0 (0%) 
  Salivary Hypersecretion 1 (14%) 0 (0%) 
  Scabies Infestation 1 (14%) 0 (0%) 
  Sciatica 1 (14%) 0 (0%) 
  Scratch 1 (14%) 0 (0%) 
  Seasonal Allergy 2 (29%) 0 (0%) 
  Self Esteem Inflated 1 (14%) 0 (0%) 
  Sensation Of Blood Flow 1 (14%) 0 (0%) 
  Sensation Of Heaviness 2 (29%) 0 (0%) 
  Sensation Of Pressure In Ear 1 (14%) 0 (0%) 
  Sensory Disturbance NOS 1 (14%) 0 (0%) 
  Sexual Dysfunction 1 (14%) 0 (0%) 
  Sexual Dysfunction NOS 1 (14%) 0 (0%) 
  Sialoadenitis NOS 1 (14%) 0 (0%) 
  Sinus Congestion 2 (29%) 0 (0%) 
  Sinus Headache 2 (29%) 0 (0%) 
  Sinus Pain 2 (29%) 0 (0%) 
  Sinusitis 1 (14%) 0 (0%) 
  Sinusitis NOS 1 (14%) 0 (0%) 
  Skin Irritation 1 (14%) 0 (0%) 
  Skin Laceration 2 (29%) 0 (0%) 
  Skin Lesion NOS 1 (14%) 0 (0%) 
  Skin Ulcer 1 (14%) 0 (0%) 
  Sleep Disorder 1 (14%) 0 (0%) 
  Sleep Talking 1 (14%) 0 (0%) 
  Sleep Walking 1 (14%) 0 (0%) 
  Sluggishness 2 (29%) 0 (0%) 
  Speech Disorder 1 (14%) 0 (0%) 
  Spinal Fracture NOS 1 (14%) 0 (0%) 
  Staphylococcal Infection 1 (14%) 0 (0%) 
  Stomach Discomfort 1 (14%) 0 (0%) 
  Stomatitis 1 (14%) 0 (0%) 
  Streptococcal Infection 1 (14%) 0 (0%) 
  Stress Symptoms 1 (14%) 0 (0%) 
  Subcutaneous Nodule 1 (14%) 0 (0%) 
  Suicidal Ideation 2 (29%) 0 (0%) 
  Suicide Attempt 2 (29%) 0 (0%) 
  Sunburn 1 (14%) 0 (0%) 
  Suspiciousness 1 (14%) 0 (0%) 
  Sweating Increased 1 (14%) 0 (0%) 
  Swollen Tongue 1 (14%) 0 (0%) 
  Syncope 2 (29%) 0 (0%) 
  Tachycardia 1 (14%) 0 (0%) 
  Tachycardia NOS 1 (14%) 0 (0%) 
  Tendonitis 1 (14%) 0 (0%) 
  Tension 1 (14%) 0 (0%) 
  Tension Headache 2 (29%) 0 (0%) 




  Thirst 2 (29%) 0 (0%) 
  Thought Blocking 1 (14%) 0 (0%) 
  Throat Tightness 2 (29%) 0 (0%) 
  Tinea Versicolor 1 (14%) 0 (0%) 
  Tinnitus 2 (29%) 0 (0%) 
  Tongue Coated 1 (14%) 0 (0%) 
  Tongue Disorder 1 (14%) 0 (0%) 
  Tongue Disorder NOS 1 (14%) 0 (0%) 
  Tonsillitis 1 (14%) 0 (0%) 
  Tooth Disorder NOS 1 (14%) 0 (0%) 
  Tooth Extraction 1 (14%) 0 (0%) 
  Tooth Extraction NOS 1 (14%) 0 (0%) 
  Tooth Infection 2 (29%) 0 (0%) 
  Tooth Injury 1 (14%) 0 (0%) 
  Tooth Loss 1 (14%) 0 (0%) 
  Toothache 2 (29%) 0 (0%) 
  Trismus 1 (14%) 0 (0%) 
  Upper Respiratory Tract Infection NOS 1 (14%) 0 (0%) 
  Urinary Hesitation 2 (29%) 0 (0%) 
  Urinary Incontinence 2 (29%) 0 (0%) 
  Urinary Retention 1 (14%) 0 (0%) 
  Urinary Tract Infection 1 (14%) 0 (0%) 
  Urinary Tract Infection NOS 1 (14%) 0 (0%) 
  Uterine Cyst 1 (14%) 0 (0%) 
  Uterine Fibroids 1 (14%) 0 (0%) 
  Uterine Spasm 1 (14%) 0 (0%) 
  Vaginosis Fungal NOS 1 (14%) 0 (0%) 
  Vasectomy 1 (14%) 0 (0%) 
  Ventricular Extrasystoles 1 (14%) 0 (0%) 
  Vertigo 2 (29%) 0 (0%) 
  Viral Infection 1 (14%) 0 (0%) 
  Viral Infection NOS 1 (14%) 0 (0%) 
  Viral Upper Respiratory Tract Infection 1 (14%) 0 (0%) 
  Vision Blurred 2 (29%) 0 (0%) 
  Visual Acuity Reduced 1 (14%) 0 (0%) 
  Visual Disturbance 1 (14%) 0 (0%) 
  Vomiting 1 (14%) 0 (0%) 
  Vomiting NOS 1 (14%) 0 (0%) 
  Weight Decreased 2 (29%) 0 (0%) 
  Weight Increased 2 (29%) 0 (0%) 
  Yawning 1 (14%) 0 (0%) 
Named serious adverse events   
  Depression 2 (29%) 1 (14%) 
  Accidental Overdose 1 (14%) 0 (0%) 
  Acute Myocardial Infarction 1 (14%) 0 (0%) 
  Acute Psychosis 1 (14%) 0 (0%) 
  Adnexa Uteri Pain 1 (14%) 0 (0%) 
  Asthma NOS 1 (14%) 0 (0%) 





  Chest Pain 1 (14%) 0 (0%) 
  Cholecystitis NOS 1 (14%) 0 (0%) 
  Conversion Disorder 1 (14%) 0 (0%) 
  Convulsion 1 (14%) 0 (0%) 
  Convulsions NOS 1 (14%) 0 (0%) 
  Death 2 (29%) 0 (0%) 
  Deep Vein Thrombosis 1 (14%) 0 (0%) 
  Drug Hypersensitivity 1 (14%) 0 (0%) 
  Duodenal Ulcer Hemorrhage 1 (14%) 0 (0%) 
  Ectopic Pregnancy 1 (14%) 0 (0%) 
  Hallucination, Auditory 1 (14%) 0 (0%) 
  Hemiparesis 1 (14%) 0 (0%) 
  Hernia NOS 1 (14%) 0 (0%) 
  Hip Fracture 1 (14%) 0 (0%) 
  Influenza Like Illness 1 (14%) 0 (0%) 
  Injury 1 (14%) 0 (0%) 
  Intervertebral Disc Herniation 1 (14%) 0 (0%) 
  Intestinal Obstruction NOS 1 (14%) 0 (0%) 
  Major Depressive Disorder NOS 1 (14%) 0 (0%) 
  Mania 1 (14%) 0 (0%) 
  Mental Status Changes 1 (14%) 0 (0%) 
  Migraine NOS 1 (14%) 0 (0%) 
  Mitral Valve Prolapse 1 (14%) 0 (0%) 
  Non-Accidental Overdose 1 (14%) 0 (0%) 
  Pancreatitis NOS 1 (14%) 0 (0%) 
  Prostatitis 1 (14%) 0 (0%) 
  Spinal Fracture NOS 1 (14%) 0 (0%) 
  Suicidal Ideation 2 (29%) 0 (0%) 
  Suicide Attempt 2 (29%) 0 (0%) 
  Syncope 1 (14%) 0 (0%) 




Appendix Figure 2-1. Number of sources of each type  
Appendix Figure 2-1 Legend: FDA=Food and Drug Administration; CSR=clinical study report; IPD=individual 
participant data.   
Panel 2-1a. Gabapentin for neuropathic pain  
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Background: Informed healthcare decisions should be based on evidence about both 
the effectiveness and adverse events (AEs) of interventions. AEs that are suspected of 
being related to an intervention may be collected “systematically” (e.g., through a 
specific interview question about whether the AE has occurred or administration of a 
laboratory test).  The objectives of this study were to describe, across eligible 
randomized controlled trials (RCTs), the collection and reporting of AEs collected 
systematically (“systematic AEs”) and to compare systematic AE reporting in “public” 
(e.g., journal articles, conference abstracts) and “non-public” (e.g., clinical study reports 
[CSRs], individual patient data [IPD]) sources.  
Methods and Findings: We performed a cross sectional analysis of the Multiple Data 
Sources (MUDS) study data. In the MUDS study, we examined consistency across the 
various sources of information about RCTs of both gabapentin for neuropathic pain and 
quetiapine for bipolar depression. Because the gabapentin RCTs did not report any 
systematic AEs, this analysis included only quetiapine RCTs. We identified public and 
non-public sources available by January 26, 2015. We extracted data from each source 
and compared reporting about systematic AEs in each of the following six pre-specified 
outcome domains: cardiovascular effects, cholesterol, endocrine effects, extrapyramidal 
symptoms, mania, and weight. Each systematic AE “outcome” included five elements: 
outcome domain, specific measurement, specific metric, method of aggregation, and 




compared what was reported for each outcome in public and non-public sources. We 
assessed whether reported results were “meta-analyzable” (i.e., one could calculate 
between-group effect estimates) and compared public and non-public sources. We 
compared the number of unique defined outcomes (i.e., an outcome was counted once, 
regardless of how many times outcome was named) in public and non-public sources. 
We identified seven eligible trials reported in 51 sources (including one IPD). Including 
both public and non-public sources, 1/6 pre-specified AE outcome domains (mania) was 
reported for all seven trials, and 3/7 trials reported meta-analyzable results related to 
mania. Public sources reported less complete information about results: about half 
(90/159; 57%) of all results reported in public sources were both associated with 
defined outcomes and meta-analyzable, compared with nearly all (610/636; 96%) 
results reported in non-public sources. Public sources also reported fewer unique 
outcomes compared with non-public sources (38 vs. 113).  
Conclusions and Relevance: To effectively compare different potential interventions, 
systematic AE outcomes must be consistently collected and reported across trials. 
Systematic AEs are often reported only in non-public sources, where more meta-
analyzable data are also found. All trial information should be available to the public so 
that the entire body of evidence is considered as the basis for treatment decisions and 
guideline creation. This is particularly true for systematic AEs, which represent 
important concerns for patients and are selected for systematic collection because of 





When choosing a health intervention, patients and clinicians need accurate and 
complete information about potential benefits and adverse events (AEs) to inform their 
decision. Outcomes that assess potential benefits are typically collected systematically 
by using, for example, closed-ended interview questions or laboratory tests, as part of 
randomized controlled trials (RCTs). In contrast, AEs can be collected using both 
systematic and non-systematic methods. Non-systematic AEs are either unsolicited by 
investigators or collected using broad, open-ended questions such as “have you noticed 
any symptoms since your last examination?” Because systematic methods of data 
collection are the same for every participant within a trial, investigators may use 
systematic methods when they suspect that a particular AE is related to an intervention. 
The understanding of which AEs may be related to an intervention often evolves as 
more data accumulate, potentially informing whether additional AEs should be collected 
systematically in subsequent studies. More often, however, AEs are collected using non-
systematic methods, and some trials do not collect any AEs systematically (4).  
The “systematic” and “non-systematic” terminology to describe different 
methods of AE data collection was established by the Final Rule, which establishes and 
clarifies federal reporting requirements for ClinicalTrials.gov (5, 6). Although the Food 
and Drug Administration (FDA) makes a similar distinction between methods of AE data 
collection, it uses different terminology (20). The FDA states that “[p]otential problems 




should be targeted for evaluation” (13); however, we were unable to find any evidence 
that the FDA  has policies requiring that any or specific AEs be collected systematically 
(13, 19, 20). Therefore, even when investigators conducting trials elect to collect certain 
AEs systematically, there may not be a core set of specific AE outcomes collected in all 
trials about particular conditions or interventions. The result of this individualistic 
approach is that different trials for the same indication and intervention may collect 
data about different AE outcomes, even when some data collection is systematic within 
the individual RCT.  
All outcomes, including effectiveness outcomes and AEs, can be defined using a 
framework that includes five elements, although this framework is not always applied: 
(1) domain (e.g., mania); (2) specific measurement (e.g., Young Mania Rating Scale); (3) 
metric (e.g., a participant’s change in Young Mania Rating Scale from baseline); (4) 
method of data aggregation for analysis (e.g., mean Young Mania Rating Scale score, 
proportion of participants reaching a particular threshold); and (5) time-point at which 
the outcome was assessed (11, 12). Because systematic AEs are collected using pre-
specified questions and methods, this framework can be used; non-systematic AEs are 
collected using open-ended questions without a specific measurement tool, however, 
and therefore this framework is not applicable.  
Results of RCTs may be made available in a variety of sources, including both 
public (e.g., journal articles) and non-public (e.g., clinical study reports [CSRs]) sources. 




public sources about the same trial (46, 48, 50, 69, 220), and different public sources 
may contain different information (38, 39, 88, 89, 220). Access to partial information, 
such as that contained in public sources alone, may impact the perceived balance of 
potential benefits and AEs if information is differentially reported in public and non-
public sources.   
In the current study, our objectives were to describe collection and reporting of 
systematic AEs identified in RCTs of quetiapine for bipolar depression across multiple 
sources of data, and to compare reporting of AEs in public and non-public sources. Our 
investigation of non-systematic AEs is reported elsewhere (220). 
Methods  
This analysis is a sub-study of the Multiple Data Sources (MUDS) study, a cross-
sectional study that compares reporting of RCTs in public and non-public sources. The 
protocol (81) and protocol amendments (90) provide additional details about the MUDS 
study methods. We have also reported additional details in Appendix 3-1 (220). 
Eligible trials and sources 
Briefly, eligible studies were parallel RCTs that compared either gabapentin for 
neuropathic pain in adults or quetiapine for bipolar depression in adults with placebo; 
participants and providers were masked (220). In the current study, we report only on 
the quetiapine RCTs, because neither the public or non-public sources for gabapentin 
trials reported any systematic AEs. The six gabapentin CSRs did, however, report that 




to journal articles, short reports (i.e., conference abstracts, commentaries, posters), trial 
registrations and associated results, and medical and statistical reviews created by the 
FDA. We use “non-public sources” to refer to CSRs, CSR-synopses, and IPD, because they 
are usually not available to the public. We searched for public and non-public sources 
and requested additional non-public sources from the company that manufactures 
quetiapine (see Appendix 3-1 and protocol (81) for additional details). 
Data extraction 
We classified AEs as systematic or non-systematic (5, 6). We pre-specified that 
we would classify AEs as systematic when they were reported as being obtained using 
specific measurement tools such as questionnaires, checklists, laboratory tests, and 
clinical examinations that were done on every patient. All other AEs were classified as 
non-systematic (220). Our analysis in this study focused exclusively on systematic AEs. 
Two investigators independently extracted data about AEs using the open access 
Systematic Review Data Repository (SRDR; http://srdr.ahrq.gov/) and resolved any 
differences by discussion. For systematic AEs, we extracted information from each 
source about the five elements of each outcome for the time-point closest to 8 weeks 
(11, 12). We extracted all outcomes and results within each of the following pre-
specified systematic AE outcome domains: cardiovascular effects, cholesterol, endocrine 




Analysis of IPD 
When IPD databases were not available, we used ABBYY FineReader (91) to 
reconstruct databases using tables of IPD (in PDF format) in the appendices of CSRs. For 
continuous outcomes in the available IPD, we calculated the mean change from baseline 
for the time-point closest to eight weeks for each specific measurement. For 
dichotomous outcomes, we calculated the proportion of participants who experienced 
each AE outcome. We calculated between group effects for both continuous (mean 
difference between groups) and dichotomous (risk difference) outcomes. We replicated 
the methods for handling missing data used in the original trials. We performed all 
analyses in Stata 14 (92). 
Outcome domains collected and reported in each trial 
Because of the detailed methods reported in CSRs (see Table 3-1) (42), we 
considered CSRs the reference for which systematic AEs were collected during the trial. 
For trials with available CSRs, we determined whether each trial collected each of the six 
pre-specified AE outcome domains. For all trials, we determined whether any public or 
non-public source reported any of the six pre-specified AE outcome domains.  
Completeness of outcome reporting in different types of sources 
We described results as “meta-analyzable” when we could calculate between 
group effects (e.g., mean difference between groups, risk difference) (63).We assessed 
whether each reported result was associated with a “defined” outcome (i.e., all five 




analyzable and associated with defined outcomes. We then compared these 
proportions for public and non-public sources. This analysis includes results associated 
with both unique outcomes (i.e., defined outcomes counted only once regardless of 
how many times they appeared, Table 3-1) and non-unique outcomes (i.e., defined and 
undefined outcomes counted each time they appear, Table 3-1). Results could be meta-
analyzable, but not associated with a defined outcome. For example, a source might 
include both a mean and standard deviation for participants’ scores on a particular 
questionnaire, but not report the time-point.  
Comparison of unique outcomes across sources 
We counted the number of unique AE outcomes and the number of unique 
outcomes with meta-analyzable results. We then compared public and non-public 
sources, as well as specific sources (e.g., journal articles, CSRs). We calculated the 
number of unique AE outcomes both across all eligible trials and for each trial 
separately.  
Meta-analyzable results reported in public and non-public sources 
For each trial, we compared the effect estimates (i.e., comparing quetiapine with 
placebo) in public and non-public sources. For continuous outcomes, we calculated a 
standardized mean difference (SMD). For dichotomous outcome, we calculated a risk 







We identified seven eligible trials of quetiapine for bipolar depression reported 
in 51 sources, including 46 (90%) public sources and one IPD. Most public sources were 
short reports (24/46, 52%) and journal articles (15/46, 33%). We obtained CSRs for two 
trials and CSR-synopses for two additional trials (Appendix Figure 3-1). 
We requested additional non-public sources from the company sponsoring all 
seven eligible quetiapine trials; our request was denied, however (93). One of the two 
CSRs had extensive appendices; from other information in the CSR, we believe that the 
IPD tables in this CSR were complete. The IPD tables in this CSR included data about 
systematic AEs. The second CSR had fewer appendices available and did not contain any 
IPD tables that included any systematic AEs. Because we did not obtain any IPD related 
to systematic AEs for this trial, we counted only the first trial as having IPD in this 
analysis. 
Summary data in CSRs matched reanalyzed IPD 
We had IPD related to systematic AEs for only one trial (Calabrese 2004). The IPD 
contained information about all of the outcome domains and specific measurements we 
found in the corresponding CSR (i.e., all questionnaires, laboratory tests, and vital signs 
for which we found aggregate data in the CSR were available in the IPD). When we 
analyzed the IPD, we found results that were similar (within rounding error) or identical 




Outcome domains were not collected and reported consistently across trials 
Although some AEs were collected systematically, eligible trials did not collect 
and report the same AEs. From the CSRs, we were able to determine which outcomes 
were collected systematically in two trials. For the remaining five trials without CSRs, we 
were unable to differentiate between outcomes that were not collected and outcomes 
that were collected but not reported.  Not all of our pre-specified outcome domains 
were collected in all trials: for example, the two trials for which we have CSRs did not 
collect any systematic AEs in the endocrine effects domain, but two other trials reported 
outcomes within this domain.  
Only one pre-specified AE outcome domain, “mania,” was reported for all seven 
eligible trials, although the outcome data were meta-analyzable in only 3/7 trials (Table 
3-2). The outcome domains with the largest number of trials that could be included in a 
meta-analysis were weight and cholesterol: in both cases 5/7 trials reported at least one 
meta-analyzable result in at least one source, public or non-public. For cholesterol, 
however, meta-analyzable results were reported in only non-public sources for two of 
these trials (Table 3-2).  
Public sources reported less information than non-public sources about outcomes and 
results  
Results in public sources were less likely to be meta-analyzable and associated 
with defined outcomes than results in non-public sources. More than half (90/159; 57%) 




defined outcomes, compared with nearly all (310/636; 96%) results reported in non-
public sources (Table 3-3). Most of the results (138/159; 87%) reported in public sources 
were found in journal articles. Journal articles were the only public source to include 
meta-analyzable results associated with defined outcomes. 
Although we had public sources for 7/7 trials and non-public sources for 4/7 
trials, public sources reported fewer unique outcomes than non-public sources (38 vs. 
113, respectively). Public sources reported meta-analyzable results for 28/38 (74%) 
unique outcomes, while non-public sources reported meta-analyzable results for 
112/113 (99%) unique outcomes. We found that different kinds of public sources (e.g., 
journal articles, trial registrations) reported different numbers of unique outcomes 
(Appendix Table 3-2).   
Meta-analyzable results reported in public and non-public sources for two trials 
Two trials included meta-analyzable results in both public and non-public 
sources (Calabrese 2004 and Thase 2006). Journal articles were the only public sources 
with meta-analyzable results (Figure 3-1). CSRs for both trials reported meta-analyzable 
results; we also had meta-analyzable results in IPD for Calabrese 2004. The non-public 
sources about both trials reported many different meta-analyzable results about each of 
the five outcome domains they assessed (Figure 3-1). Many results were related to each 
outcome domain because of variations in the specific measurement, metric, and 
method of aggregation (note that we extracted data for only one time-point). For 




two different questionnaires: the Barnes Akathisia Rating Scale and the Simpson-Angus 
Scale. 
For Calabrese 2004 and Thase 2006, we found meta-analyzable results in both 
public and non-public sources for three outcome domains: mania, weight, and 
extrapyramidal symptoms (Figure 3-1). Although results were often unreported in public 
sources, they appeared to agree with results in non-public sources when they were 
reported (Figure 3-1). 
Discussion  
Although certain AEs were systematically collected, not all trials systematically 
collected and reported the same AEs. We were able to determine which outcome 
domains were collected using CSRs for two trials. For the five trials for which we did not 
have CSRs or IPD, we were unable to determine which outcome domains were not 
collected and which outcome domains were collected but not reported.  
When trials do not assess the same AEs, as occurred in this analysis, healthcare 
decisions may be based on some of the available trials. Core outcome sets (“an agreed 
minimum set of outcomes” (23, 24)) could improve consistency across trials by 
identifying systematic AEs that should be assessed in all trials of a condition or 
intervention. Typically, core outcome sets are associated with a particular disease or 
condition (24), but this may be inappropriate when assessing AEs. Different types of 
interventions (e.g., psychotherapy vs. pharmaceutical interventions) may cause different 




used to treat bipolar depression and schizophrenia). Therefore, it may be more 
appropriate to have a core outcome set of systematic AEs for an intervention or group 
of interventions (e.g., a drug class), rather than a condition.  
To improve estimates of the probability that patients will experience AEs, and to 
permit comparisons across trials, investigators might collect anticipated AEs 
systematically. It can be difficult to anticipate which AEs will occur in the first clinical 
trials of a drug or class of drugs, so investigators often collect information about many 
AEs non-systematically. In later trials, investigators could use evidence from early trials 
to anticipate which AEs might occur.  Because evidence accumulates over time, core 
outcome sets may need to be periodically updated to incorporate the latest evidence.  
Using systematic and non-systematic methods to collect data about AEs can lead 
to different results (15, 18, 221). For example, patients may be more likely to report an 
AE when systematic methods are used (15). Thus, we question whether it is appropriate 
to compare the relative safety of different interventions when trials used different 
methods to assess AEs.  
Although most AEs are collected non-systematically, it may be more valid and 
reliable to use systematic methods to collect AEs. Validity and reliability are critical 
indicators of measurement quality (222). There are well-established methods for 
assessing the validity and reliability of instruments, such as those used in systematic 
data collection (222-224). Because non-systematic methods do not utilize instruments, 




systematic AEs. Using valid and reliable instruments to collect AEs systematically will 
improve the quality of research.  
The five elements of an outcome (11, 12) should be pre-specified for systematic 
AEs. As we and others have shown (63), variations in these elements can lead to a very 
large number of outcomes and associated results within a single trial and across 
multiple trials. If the five elements and the methods of analysis are not pre-specified, 
trialists and systematic reviewers may “cherry-pick” outcomes based on their results 
(63).  
Both results and details about collection methods should be made public so that 
decision-makers can take all evidence about benefits and AEs into account. The 
Consolidated Standards of Reporting Trials (CONSORT) extension for harms provides 
specific reporting standards (36). We did not find that this information was typically 
available in public sources or CSR-synopses. From our findings we surmise that 
ClinicalTrials.gov may not be a good source of information about trials conducted before 
registration and results policies were in place, although we only have evidence about 
one intervention. We were unable to identify any FDA reviews of quetiapine for bipolar 
depression, so further research is needed to determine if FDA reviews contain more 
information about systematic AEs than other public sources. Increased accessibility of 
FDA reviews is important; they are currently unavailable to the public in some cases. If 




their content) and methodological information (e.g., how AEs were collected) should 
also be shared to increase transparency.  
Non-public sources are often unavailable and, as with the other intervention we 
examined in MUDS (gabapentin for neuropathic pain), AEs may not be collected 
systematically. Although our analysis focused on a single intervention, our findings are 
consistent with other studies about AE collection and reporting. This suggests that our 
recommendations (Box 3-1) may be applicable in a broader context. For trials that are 
being conducted and published now, adherence to the existing guidelines for reporting 
AEs (36) could improve the quality and amount of AE data reported. For trials that have 
already been published, however, further steps should be taken. Our findings here are 
consistent with those that suggest access to non-public sources may be critical to 











Adverse events that are collected using open-ended questions or are 
spontaneously reported by participants. For example, adverse events 
collected by asking participants questions like “Have you noticed any 




Adverse events that are collected in the same manner for each participant 
using methods related to specific adverse events. For example, adverse 
events collected using validated questionnaires, checklists, laboratory 
measurements, or vital signs.  
Sources 
 Public sources1 In this study, public sources include journal articles, conference abstracts, 
commentaries, posters, trial registrations and associated results, and 




In this study, non-public sources include individual patient data, clinical 
study reports, and clinical study report-synopses. 
 Clinical study 
report (CSR)1 
A comprehensive document created by a pharmaceutical company 
detailing the design, methods, analyses, and results of a single study for 
submission to regulatory agencies. The clinical study reports we examined 
ranged in length from 1315 to 8027 pages. Appendices contain tables of 
individual participant data, also called “patient data listings.”  
 Clinical study 
report synopsis 
(CSR-synopsis)1 
An internal company document that summarizes the information 
contained in clinical study reports. Clinical study report-synopses are 
much shorter than clinical study reports; the two clinical study report-




Each record lists data separately for each participant. In the below 
example, the data include a participant identifier (“PTNO”), text 
describing the adverse event (“AETX”), whether the AE was classified as 
serious (“AESER”), the day of the study that the event occurred 
(“SDAESTDY”), and a standardized code for grouping AEs that are clinically 
equivalent (“AE”; e.g., “giddy” and “giddiness” have the same code). 
There is a separate record for each participant and each different AE. For 
example, participant 167 experienced three different AEs (tiredness, 
headache, and septic foot).  
 
 




 Outcome2 An event in a person, used to assess a treatment’s effect (226). May be 
defined using all elements or not defined. 
 Defined 
outcome2 
Includes all five elements of an outcome: (1) outcome domain, (2) specific 
measurement, (3) specific metric, (4) method of aggregation, and (5) 
time-point. For example “proportion of participants with 50% change 
from baseline to 8 weeks on the Young Mania Rating Scale total score.” 
 Not defined 
outcome2 
Includes the name of an outcome domain but does not include one or 
more of the other 4 elements; for example, “symptoms of mania at 8 
weeks.” 
 Result2 A numerical contrast between a treatment and comparison group (e.g., 
relative risk, mean difference). 
 Meta-analyzable 
result2 
A result for which sufficient information was provided to calculate the 
between group effect (e.g., a point estimate and a measure of precision). 
 Unique 
outcome2 
Defined outcome which is counted only once, regardless of how many 
times it appeared in all sources. 
 Non-unique 
outcome2 
Outcome counted each time it appears in sources. Note that if the same 
outcome is reported more than once in the same source (e.g., in text and 
in a table), it is counted just once for that source. 
1 Item identical to an item used in our research on non-systematic AEs (220). 





Table 3-2. Trials reporting each adverse event outcome domain in public sources, 
overall and with meta-analyzable results 








Trial reporting AE outcome domain in public sources 
Calabrese 
2004 
      
Gao 2014    *   
Li 2014     *  
McElroy 
2010 
    *  
Suppes 2010    * *  
Thase 2006       
Young 2008    * *  
Legend:  
* At least one public source for that trial reported at least one result within the outcome domain.  






Table 3-3. Proportion of results that are meta-analyzable and associated with 
defined adverse event outcomes, by source 
 Public Sources (n=159)   Non-Public Sources (n=636) 
Meta-analyzable result? Defined outcome? Defined outcome? 
 Defined Not defined Defined Not defined 
Meta-analyzable 90 (57%) 2 (1%) 610 (96%) 20 (3%) 
Not meta-analyzable 35 (22%) 32 (20%) 2 (0.3%) 4 (0.6%) 
         
 Journal Articles (n=138) Other Public Sources (n=21) 
Meta-analyzable result? Defined outcome? Defined outcome? 
 Defined Not defined Defined Not defined 
Meta-analyzable 90 (65%) 2 (1%) 0 (0%) 0 (0%) 






Figure 3-1. Systematic adverse event outcomes in public and non-public sources 
for two trials  
Legend: This figure includes the two trials that reported meta-analyzable results in both public and non-
public sources. While non-public sources about each trial included hundreds of results, public sources 
included fewer than 10 results and omitted outcome domains included in non-public sources. 
SMD=standardized mean difference (used for continuous outcomes); RD=risk difference (used for 







Recommendations for adverse event collection and reporting 
1. Describe collection methods for each adverse event (AE) in the trial protocol and provide 
case report forms;  
2. Develop, regularly update, and use a core outcome set for AEs for interventions or groups of 
interventions (e.g., drug class);  
3. Incorporate both potential AEs and potential benefits into the design and reporting of a trial; 
4. Report defined outcomes and meta-analyzable results for AEs; 
5. Collect data on known AEs systematically;  
6. Use preclinical studies and trials of other drugs in the same class to inform systematic AE 
collection;  
7. Make results of all AEs, collection and analysis methods, and full outcome definitions, 
available to the public; one potential mechanism is for the FDA to release the information 






Appendix 3-1. Detailed methods 
Identifying sources about eligible trials 
We searched both the International Clinical Trials Registry Platform Search Portal (ICTRP) and 
ClinicalTrials.gov for trial registrations and associated results related to gabapentin or quetiapine on 
October 10, 2014. We searched PubMed, Embase, Lilacs, CINAHL and the Cochrane Central Register of 
Controlled Trials (CENTRAL) for gabapentin and quetiapine sources, as well as PsycInfo for quetiapine; we 
completed our searches March 2, 2015 (gabapentin) and January 26, 2015 (quetiapine), without any 
language restrictions. We identified medical and statistical reviews of gabapentin as well as quetiapine 
available on the FDA website (26). We also searched certain conference proceedings and years for 
gabapentin trials (see protocol (81)). We searched online (http://psychrights.org/) for typically non-public 
sources about quetiapine for bipolar depression. We requested non-public sources in the form of internal 
company documents from the manufacturers of gabapentin and quetiapine (Pfizer and AstraZeneca, 






Appendix Table 3-1. Systematic adverse event outcome domains and 
measurements identified  
Adverse Event Outcome Domains Adverse Event Outcome Specific Measurements 
Cardiovascular effects Pulse 
Systolic blood pressure 







Endocrine effects Serum prolactin 
Extrapyramidal symptoms Barnes Akathisia Rating Scale (BARS) 
Simpson-Angus Scale (SAS) 
Mania Young Mania Rating Scale (YMRS) 
Weight Weight 






Appendix Table 3-2. Number of unique, defined, systematic adverse event outcomes in public and non-public sources, by 
trial  
Trial Identifier 
Public Sources Non-Public Sources 
All 
Sources 
Journal Articles Short Reports 
ClinicalTrials.gov All Public CSR CSR-S 
All Non-
Public 1 Trial >1 Trial Abstracts Other 
All MA
 
All MA All MA All MA All MA All MA All MA All MA All MA All MA 
Calabrese 2004 
(170-195) 
7 4 0 0 0 0 0 0 0 0 7 4 98 98 NA NA 98 98 99 99 
Gao 2014 (196, 
197) 
3 1 NA NA NA NA NA NA 0 0 3 1 NA NA NA NA NA NA 3 1 




22 20 0 0 0 0 0 0 0 0 22 20 NA NA 1 0 1 0 23 20 
Suppes 2010 (205-
207) 
15 7 NA NA 0 0 NA NA 0 0 15 7 NA NA NA NA NA NA 15 7 
Thase 2006 (170-
180, 208-213) 




16 12 0 0 0 0 0 0 0 0 16 12 NA NA 0 0 0 0 16 12 
Total 38 28 0 0 0 0 0 0 1 0 38 28 1 0 112 112 113 112 127 124 
MA=meta-analyzable; NA=not applicable because we did not identify any sources of this type; CSR=clinical study report; CSR-S=CSR-synopsis. Note that 
individual patient data (IPD) were not included in this table because some elements of a defined outcome are not applicable to IPD; for example, IPD are not 
aggregated, so there is no method of aggregation.  




Appendix Figure 3-1. Number of sources of each type 
FDA=Food and Drug Administration; CSR=clinical study report; IPD=individual participant data (note that 





























Chapter 4. Aim 3 
 
Opportunities for selective reporting of non-systematic adverse events in 
randomized controlled trials 
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Background: In randomized controlled trials (RCTs), most adverse events (AEs) are 
collected non-systematically (e.g., experience of the AE was not solicited). Although 
RCTs may be reported in multiple sources, AEs may not always be reported. The 
objectives of this study were to (1) compare “selection criteria” (i.e., reported methods 
for selecting which AEs to report from an RCT) for reporting non-systematic AEs; (2) 
determine how different selection criteria could affect AE reporting; and (3) assess how 
different selection criteria could impact the results of meta-analyses of AEs.  
Methods: We compared data sources (e.g., journal articles, clinical study reports) about 
RCTs examining either gabapentin for neuropathic pain or quetiapine for bipolar 
depression (data available by March 2, 2015 and January 26, 2015, respectively). We 
extracted and compared information about selection criteria for reporting non-
systematic AEs and assessed how the choice of selection criteria impacted AEs reported. 
We simulated meta-analyses of AEs in small and large RCTs, assuming different “true” 
proportions of patients experiencing the AE in each trial and assessed whether the AE 
would have been reported, based on the numerical threshold (e.g., ≥5%) for reporting. 
Results: We identified 21 gabapentin trials and 7 quetiapine trials. Although the 
majority of sources included non-systematic AEs, AEs were chosen for reporting based 
on selection criteria and represented a subset of the AEs that occurred. We found no 
evidence in study protocols that selection criteria were pre-specified. The choice of 




reported for all trials. For example, while all trials we observed would report many AEs if 
the selection criterion was “occurred in ≥1% of any intervention group,” trials would 
report few AEs if the selection criterion was “occurred in ≥10% of all participants.” Our 
simulations showed that the choice of different selection criteria could result in either 
(1) meta-analyses of non-systematic AEs incorrectly indicating no harmful effect of the 
intervention or (2) no possible meta-analyses because of unreported AEs. 
Conclusions: By not pre-specifying selection criteria for reporting, trialists can “cherry-
pick” which AEs to report. Data about all non-systematic AEs identified in trials must be 






The effectiveness and safety of health interventions may be considered best 
assessed through randomized controlled trials (RCTs) (227), and regulatory approval is 
typically based on the results of RCTs (4). Effectiveness outcomes are typically used to 
estimate sample size and power of a trial to detect a true difference between 
treatments (4), but RCTs are not typically powered to detect differences the occurrence 
of adverse events (AEs) in the study population (see Table 4-1 for a glossary of terms 
used) (72). Because regulatory agencies require the collection of non-systematic AEs 
(i.e., the occurrence of an AE is ascertained either from unsolicited reporting by 
participants or from general questions such as “have you noticed any changes since your 
last visit?” (5, 6)) (4, 21), our understanding is that information about the experience of 
most AEs is collected using non-systematic methods. AEs can also be collected 
systematically, using, for example, questionnaires, checklists, and laboratory tests (5, 6). 
Unlike non-systematic AEs, systematic AEs are typically pre-specified during trial design 
(5).  
Systematic reviews and meta-analyses provide the opportunity to combine AE 
data from multiple RCTs, which, because AEs usually occur infrequently, may allow the 
detection of between-group differences not identified in individual RCTs. Although more 
resources are becoming available through data sharing initiatives (228, 229), systematic 
reviews and meta-analyses of AEs typically rely on AE data that have been publicly 




Existing evidence shows that the results of RCTs may not be made publicly 
available (56, 58), and that even when RCTs are published, reporting may be incomplete 
(58-63, 71, 90, 220, 230). Outcome reporting bias, defined as the “selective reporting of 
some outcomes but not others, depending on the nature and direction of the results” 
(64), may affect the findings of systematic reviews and meta-analyses that are based on 
the publicly reported results of these RCTs (65-68). The presence of outcome reporting 
bias has been well-established for effectiveness outcomes in RCTs (58-63).  
Although we know that multiple sources (e.g., journal articles, conference 
abstracts) describing the same RCT sometimes report different non-systematic AEs and 
that many non-systematic AEs are unreported in public sources (38, 39, 46, 48, 50, 69, 
88, 89, 220), there is little evidence about AE selection criteria (i.e., reported methods 
for choosing which AEs to include in a source, see Table 4-1). Non-systematic AEs that 
occur during a particular trial might meet some selection criteria, but not others. For 
example, an AE that occurred in 4% of all participants would be reported if selection 
criteria specified that AEs would be reported if they occurred in ≥2% of all participants, 
but not if selection criteria specified ≥5% of all participants.  
ClinicalTrials.gov, an important data source about trials, has different reporting 
requirements for non-systematic and systematic AEs. The Final Rule, which describes 
requirements for reporting RCTs in ClinicalTrials.gov, states that non-systematic AEs that 
occur in ≥5% of any intervention group should be entered in ClinicalTrials.gov (5). 
Because systematic AEs are pre-specified, the Final Rule states that the results of all 




“serious” AEs, defined by the Food and Drug Administration (FDA) as “death, a life-
threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substantial disruption of the 
ability to conduct normal life functions, or a congenital anomaly/birth defect” (19). We 
have shown previously that not all serious AEs are reported (220). Because guidelines 
are clear that all serious AEs and systematic AEs should be reported, while only a subset 
of non-systematic AEs should be reported, this analysis focused exclusively on non-
systematic AEs.   
The objectives of this study were to (1) compare selection criteria for reporting 
non-systematic AEs; (2) determine how different selection criteria could affect AE 
reporting; and (3) assess how different selection criteria could impact the results of 
meta-analyses of AEs for two case studies, RCTs examining gabapentin for neuropathic 
pain or quetiapine for bipolar depression.  
Methods 
This analysis is a sub-study of the Multiple Data Sources (MUDS) study, a cross-
sectional study that compares reporting of RCTs in public and non-public sources. The 
protocol (81) and protocol amendments (90) provide additional details about the MUDS 
study methods, including search strategies. We have also reported additional details in 




Eligible trials and sources 
Briefly, we defined eligible studies as parallel RCTs, in which both participants 
and providers were masked, that compared either gabapentin for neuropathic pain in 
adults or quetiapine for bipolar depression in adults compared to placebo. We use 
“public sources” to refer to journal articles, short reports (i.e., conference abstracts, 
commentaries, posters), trial registrations and associated results, and medical and 
statistical reviews created by the FDA. We use “non-public sources” to refer to clinical 
study reports (CSRs), CSR-Synopses, and individual participant data (IPD), which are 
usually not available to the public. We searched for public and non-public sources and 
requested additional non-public sources from the companies that manufacture 
gabapentin and quetiapine (see Appendix 1 and protocol (81) for additional details) 
(220). In this analysis, we focused on the reporting of trials; because IPD do not contain 
reported methods, we excluded IPD from this analysis. 
According to guidelines created by the International Conference on 
Harmonisation, CSRs should contain summary data about all AEs in clinical trials (42). 
We therefore considered CSRs the reference standard for determining which AEs 
occurred during a trial. 
Data extraction 
Two investigators independently extracted data about non-systematic AEs using 
the open access Systematic Review Data Repository (SRDR; http://srdr.ahrq.gov/) and 
resolved any differences by discussion. We extracted the name of the non-systematic AE 




experiencing an AE), if available. We extracted information about AEs even when results 
were not reported; for example, if a source reported that “the most common AEs were 
dizziness and headache,” we extracted dizziness and headache as reported AEs) (220). 
We also extracted all reported methods about how AEs were selected for inclusion in 
the source (“selection criteria”).  
Comparing AE selection criteria for reporting across sources and trials 
We assessed which sources reported non-systematic AEs, and when they were 
reported, we assessed AE selection criteria, if any. We described the different selection 
criteria reported and assessed whether multiple sources about the same trial reported 
using the same selection criteria. When possible, we described selection criteria using 
four components: 
 Numerical threshold: a cutoff for reporting the number or proportion of 
participants who reported experiencing a specific AE (e.g., ≥5% of participants).  
 Participant group: specification of which group(s) must experience a particular 
AE to be reported (e.g., participants in a specific intervention group, all 
participants in the trial).  
 Difference in frequency threshold: a cutoff for reporting a difference in the 
number or proportion of participants experiencing a specific AE, comparing one 
intervention relative with another (e.g., more frequent in one intervention 
compared to another, twice as frequent in the active intervention group 




 Statistical significance threshold: a cutoff for reporting a statistically significant 
difference in the number or proportion of a specific AE in participants receiving 
one intervention relative to another (i.e., there is a statistically significant 
difference in the frequency of AEs between the active intervention group and 
the placebo group). 
We described each reported component for all selection criteria. Below we show some 
examples of selection criteria, with each component identified by color: 
Numerical threshold for reporting 
Participant group 
Difference in frequency threshold 
Statistical significance threshold
Selection criteria example 1: 
Adverse events are reported if they occur in    ≥5%    of 
participants in any intervention group. 
 Selection criteria example 2: 
Adverse events are reported if they occur in    ≥2%    of     
participants receiving gabapentin    and if they occur    at least twice as frequently   in 
participants receiving gabapentin, compared with participants receiving placebo. 
 Selection criteria example 3: 
Adverse events are reported if they occur in    ≥1%    of    all participants    and if they 
occur    statistically significantly      more frequently    in participants receiving 




We compared which non-systematic AEs were reported in multiple sources 
about the same trial(s); we did not compare AEs reported in sources that did not report 
any selection criteria. We also compared information reported in CSRs, which included 
data about all observed AEs and did not utilize selection criteria (42), with the non-
systematic AEs in sources that reported selection criteria. For example, if a source about 
a trial reported that it included all AEs occurring in ≥5% of all participants, we used the 
CSR for the same trial to identify which AEs met this selection criterion. We then 
compared our findings from the CSR with the AEs reported in other sources. 
Applying AE selection criteria to data in individual trials 
To assess how using different selection criteria affects which and how many non-
systematic AEs would be reported, we applied multiple selection criteria to the data in 
CSRs, when CSRs were available (six gabapentin trials and two quetiapine trials). We 
used the selection criteria reported in sources about eligible studies as a basis for the 
selection criteria we applied. We combined each numerical threshold for reporting we 
identified with each participant group, difference in frequency threshold, and statistical 
significance threshold we identified. We then determined which non-systematic AEs 
would meet each of the selection criteria for each trial. For example, we examined the 
reported data for each different AE in the CSR and assessed whether each reported AE 
met the selection criterion “occurring in ≥5% of participants in any intervention group, 
with no additional requirements for difference in frequency or statistical significance.” 
We then calculated and compared the total number of different AEs that met each of 




Simulations of meta-analyses of RCTs with different AE selection criteria for reporting 
A simulation uses computer-generated data to model events in cases where real-
world data are unavailable or difficult to obtain (see Table 4-2 for the process of 
performing a statistical simulation). Because meta-analyses of AEs are typically based 
only on reported data (77), we wanted to assess how different selection criteria for 
reporting might impact the results of meta-analyses. We did this for one “realistic” 
scenario based on the small number of trials and participants typically included in 
Cochrane reviews (231-233) and one “ideal” scenario based on a large number of trials 
and participants:  
1. “Realistic” scenario: meta-analyses of few (10), smaller (100 participants per 
arm), two-arm RCTs; 
2. “Ideal” scenario: meta-analyses of many (50), large (1000 participants per arm), 
two-arm RCTs.  
Within each of these scenarios, we: 
 Varied the numerical threshold for reporting AEs while holding constant the 
other components of selection criteria (i.e., participant group, difference in 
frequency threshold, and statistical significance threshold); 
 Varied the specified “true” proportion of participants expected to experience 
the AE across all arms; once the true proportion is specified, each simulated trial 
estimates the proportion of participants with an AE in a distribution centered 




the trials may estimate that the AE occurs in 4%, 5%, or 6% of participants in a 
trial because the trial is only a sample of all potential participants. As sample size 
increases, estimates become more precise;  
 Set the odds ratio (OR) comparing two intervention groups equal to three 
(OR=3) for all simulations. We used an OR because meta-analyses of other types 
of effect estimates (e.g., relative risk, absolute risk difference) are more biased 
for rare events (64). We selected OR=3 because an OR=3 indicates that the AE is 
likely to be positively associated with an intervention (234-237);  
 Assessed the average number of studies in each simulation that reported data, 
for each true proportion and numerical threshold for reporting; 
 Plotted the average meta-analytic estimate and 95% confidence interval for (1) 
all studies and (2) studies that reported data about the AE using each numerical 
threshold for reporting, grouped by true proportion.  
All parameters for our simulations are described in Table 4-3. We performed all analyses 
using Stata 14 (92) and R 3.3.1 (238). 
Results 
Search results 
We identified reporting 21 gabapentin trials in 74 sources and reporting 7 
quetiapine trials in 50 sources. Nearly all the sources we identified were public: 68/74 
(92%) for gabapentin and 46/50 (92%) for quetiapine. One trial had no public sources 




Reporting of AE selection criteria 
Selection criteria for reporting an AE varied widely across sources:  
 We identified five different numerical thresholds: we identified four in 
gabapentin sources (1%, 2%, 3%, and 5%) and two in quetiapine sources (5% and 
10%).  
 Both gabapentin and quetiapine sources reported AEs in a variety of participant 
groups: participants in any intervention group, participants receiving gabapentin 
or quetiapine, and all trial participants.  
 For difference in frequency threshold, gabapentin sources either didn’t require 
any difference in frequency or required that AE frequency should be “higher” in 
the gabapentin group than the placebo group. Quetiapine sources either didn’t 
require a difference in frequency or required that AE frequency should be “at 
least twice as high” in the quetiapine group as the placebo group.  
 Statistical significance of the difference between intervention groups in the 
proportion of trial participants with a specific AE was not required for reporting 
in any source about either gabapentin or quetiapine. 
These components were combined in various ways to define different selection criteria 
(Figure 4-1). For example, we identified a gabapentin source that reported including AEs 
that occurred in 1% of all participants with no additional required difference in 




Few discrepancies in reported AEs across multiple sources about the same trial(s) 
When there were multiple sources describing the same trial(s), AE reporting was 
consistent most, but not all, of the time (Table 4-4). We identified two discrepancies 
between multiple sources about the same trials. We identified one discrepancy among 
multiple sources about the same trial(s) that reported using the same selection criteria 
and one discrepancy between a CSR and public sources about the same trial.  
Number of trials and sources providing AE selection criteria for reporting 
Many sources (19/74 [26%] gabapentin and 18/50 [36%] quetiapine sources) did 
not mention specific non-systematic AEs at all (i.e., either the source did not report any 
information about AEs or reported only the number of participants who experienced 
“any AE”) (Figure 4-2). Other sources (8/74 [11%] gabapentin and 10/50 [20%] 
quetiapine sources] mentioned specific AEs, but did not provide any numerical results 
(e.g., reported that common AEs included dizziness and somnolence without reporting 
either the number or proportion of participants who experienced these AEs). Although 
the majority of sources reported AEs, sources reported using selection criteria to choose 
particular AEs to report.  
One third (7/21) of gabapentin trials and all (7/7) quetiapine trials reported 
selection criteria in at least one source (Table 4-5). For trials that with selection criteria 
reported multiple sources, 1/2 (50%) gabapentin trial and 2/4 (50%) quetiapine trials 




The choice of AE selection criteria had a large impact on AEs that would be reported  
We examined the impact of selection criteria on reporting.  All components of 
selection criteria we identified in the sources were viewed together: (1) the five 
numerical thresholds (1%, 2%, 3%, 5%, and 10%); (2) the three participant groups (any 
intervention group, gabapentin or quetiapine participants, and all trial participants); and 
(3) the three differences in frequency (no difference in AE frequency between 
intervention groups, AE frequency higher in the active intervention group than in the 
placebo group, and AE frequency twice as high in the active intervention group as the 
placebo group); recall that no sources reported requiring statistical significance as part 
of the selection criteria. We combined these components we identified to form 45 
different selection criteria. 
By applying these 45 different selection criteria to the AE data reported in the 
eight CSRs we identified, we determined that the selection criteria could have a large 
impact on the number of different AEs that would be reported (Figure 4-3). For 
example, there were 91 different AEs described in CSRs for study 945-224. We found 
that 91/91 of these AEs met the selection criteria “occurring in ≥1% of any intervention 
group with no required difference in frequency.” On the other hand, 0/91 AEs met the 
selection criteria “occurring in ≥10% of all participants with no required difference in 
frequency.” Within the CSRs we examined, including the associated protocols, we did 
not identify any pre-specification of which AEs would be reported or selection criteria 




Simulations of meta-analyses indicate that certain selection criteria may lead to biased 
estimates of intervention effects 
Figures 4-4 (“realistic” scenario) and 4-5 (“ideal” scenario) show the meta-
analytic effect estimates for different proportions of participants who would have 
experienced the AE (“true proportions”), varying the numerical threshold for reporting, 
one component of selection criteria for reporting.  
For each scenario (“realistic” and “ideal”), there were 5 simulations for which the 
specified true proportion of AEs was equal to the numerical threshold for reporting. For 
both scenarios, a little more than half of the studies reported AE data for each of these 
simulations. Interestingly, although the meta-analysis did not include AE data from all 
studies, the summary effect estimate and confidence interval were very similar to that 
when AE data all studies were included in the meta-analysis. 
For each scenario (“realistic” and “ideal”), there were 10 simulations for which 
the specified true proportion of AEs was lower than the numerical threshold for 
reporting (e.g., the true proportion was 1% and the numerical threshold for reporting 
was 2%). In the “realistic” scenario, 8/10 simulations resulted in few trials reporting 
non-systematic AE data; in the remaining 2/10 simulations, no trials reported non-
systematic AE data. In the “ideal” scenario, 3/10 simulations resulted in few trials 
reporting non-systematic AE data; in the remaining 7/10 simulations, no trials reported 




When few studies reported AE data, the resulting lack of precision sometimes 
led the 95% confidence interval to include an OR of 1, indicating no evidence of an 
effect on AEs. Thus, meta-analyses based on reported data sometimes incorrectly 
showed that there was no evidence of a relationship between the intervention and the 
AE, when there was a positive association. When no studies reported AE data, no meta-
analysis could be conducted. In both scenarios, these problems happened more 
frequently when the specified true proportion was lower. 
Discussion 
Previous research has shown that non-systematic AEs are often unreported in 
public sources (38, 39, 46, 48, 50, 69, 88, 89, 220), but we are unaware of any research 
that investigates selection criteria for reporting non-systematic AEs. Although some 
sources did not report any selection criteria, we found a wide variety of reported 
selection criteria, both for each trial (across the multiple published sources available for 
many trials) and across trials. All of the selection criteria we identified reported using a 
numerical threshold (e.g., 5%) to determine which AEs to report.  
We found few discrepancies between sources that reported using the same 
selection criteria, indicating that selection criteria were usually applied consistently. We 
identified a wide variety of selection criteria, however, and the choice of selection 
criteria can have a meaningful impact on how many non-systematic AEs would be 
reported. When we applied different selection criteria to the true number of non-




that the number of different AEs that met each different selection criteria varied widely. 
For example, as the numerical threshold increased, fewer AEs would be reported; when 
the applied numerical threshold was 10%, few or no AEs would be reported. Although 
we had CSRs for only eight trials, the findings for each of these eight trials were 
consistent with each other, indicating that our results may be generalizable to other 
trials.     
We found no evidence in the CSRs or associated protocols that the selection 
criteria for reporting non-systematic AEs in other sources were pre-specified. When 
selection criteria are not pre-specified, trialists have the opportunity to determine them 
post hoc and thus can “cherry-pick” which and how many different non-systematic AEs 
they report. For example, trialists could perform an analysis similar to ours in which they 
apply different selection criteria to their data, and then determine which selection 
criteria would allow them to report and not report particular AEs. The Final Rule 
combats this problem by requiring all trials to use the same selection criteria for 
reporting non-systematic AEs in ClinicalTrials.gov (5).  
We found that using numerical thresholds, such as those we observed in sources 
about gabapentin and quetiapine, to select non-systematic AEs for reporting often leads 
to either inaccurate meta-analysis results (i.e., incorrectly concluding that there is no 
evidence of a relationship between the intervention and the AE) or an inability to 
perform meta-analyses because no data were reported. In our simulations, we found 
this to be true whether we assumed a “realistic” scenario and an “ideal” scenario; the 




having large, high-quality primary studies. Because of the consistency of our findings, we 
believe that using numerical thresholds to select non-systematic AEs for reporting is 
problematic, regardless of the intervention, condition, or trial characteristics. Our 
findings were also consistent with the existing evidence about the effect of outcome 
reporting bias on effectiveness outcomes; selectively reporting effectiveness outcomes 
based on their quantitative results can lead to biased meta-analysis results (65-68).  
In our simulations, we found that meta-analyses of rarer AEs (e.g., occurring in 
about 1% of participants) were more likely to be inaccurate because of numerical 
thresholds for reporting; this is because rarer AEs were more likely to be excluded from 
reporting based on numerical thresholds. Because trials are typically not powered to 
detect differences between intervention groups in the how often AEs occur (72), meta-
analyses of AE data from multiple trials provide an opportunity to detect true 
differences in the frequency of AEs, which are often rare (64). Thus, rare AEs, which are 
most likely to benefit from meta-analyses, are also most likely to be unreported when 
trials report AEs based on a numerical threshold. 
Although most reporting of non-systematic AEs appears to be based on a 
numerical threshold for reporting, patients are not necessarily most interested in the 
AEs that occur the most frequently(239). Most patients report that they would like to 
know information about all AEs when selecting a health intervention (239, 240), while 
others indicate that they wanted information about serious AEs that will have an impact 
on quality of life (241). The importance of serious AEs to patients appears to be 




frequent AEs (i.e., occurring in ≥5% of any treatment group). Other rare non-systematic 
AEs are still excluded from their reporting guidelines, however. Healthcare has been 
evolving to emphasize the preferences of patients (2, 242), and patient preferences 
should be incorporated into the collection and reporting of AEs. 
Based on our research, we have several recommendations about non-systematic 
AEs. First, data about all AEs should be made available to the public, including patients, 
systematic reviewers, and other healthcare stakeholders. Moving forward, trialists 
should report data about all AEs. For example, journals could require trialists to submit 
an online supplement that contains data about all AEs to accompany the journal article 
reporting trial results. It may not be feasible to report all AEs in some sources, such as 
conference abstracts that have space limitations. In those cases, reported AEs should be 
selected based on their importance to patients and other healthcare stakeholders, 
rather than their results. The source should also (1) state that only a subset of AEs are 
reported and (2) direct readers where to find data about additional AEs. For older trials 
that have already been incompletely published, making data about all AEs public may 
involve sharing sources that are typically unavailable to the public, such as CSRs. 
Although there are currently data-sharing efforts underway, many of these initiatives 
apply only to trials completed after a particular date (78-80). If trialists choose to select 
AEs for reporting based on their quantitative results, all four components of the 
selection criterion should be pre-specified to minimize opportunities for cherry-picking.  
Regardless of how AEs are selected for reporting, selection criteria should be reported 




Systematic reviewers should be aware of the potential problems of using AEs 
reported based on their quantitative results. When systematic reviewers encounter 
sources that report selecting AEs based on their quantitative results, they should 
request additional data from trial authors. If data are not made available, systematic 
reviewers should interpret any AE meta-analysis results with extreme caution and 
discuss the limitations of using only publicly available data.  
According to the National Academy of Medicine, clinical practice guidelines 
should be based on high-quality systematic reviews of the evidence (243). Systematic 
reviews and meta-analyses are typically based on publicly reported data (77). This 
means that, based on our findings, guideline developers, as well as other healthcare 
stakeholders, may be basing their recommendations on either no information or 
inaccurate information. Reporting a subset of AEs that occur during a trial, particularly if 
they are chosen for reporting based on a numerical threshold rather than their 
importance to patients and other healthcare stakeholders, is problematic for guideline 
developers, clinicians, and patients. Having the best possible evidence about a health 
intervention is important to those making healthcare decisions. For some conditions, 
such as depression, there may be many interventions available (244). Without accurate 
evidence about the potential benefits and AEs of each intervention, patients may have 
to try several different interventions to find one that is beneficial and does not cause 
any AEs, putting them at risk from both the multiple interventions and their underlying 




sharing and open science would subsequently enable healthcare stakeholders to make 





Table 4-1. Glossary of Terms  
Term Definition 
Adverse events 
 Adverse event Any untoward medical occurrence associated with  the use of a drug in 





Adverse events that are collected using open-ended questions or are 
spontaneously reported by participants (i.e., non-systematically collected). For 
example, adverse events obtained by asking participants questions like “Have 
you noticed any symptoms since your last examination?” (5). 




Adverse events that are collected in the same manner for each participant 
using methods related to specific adverse events (i.e., systematically collected). 
For example, adverse events collected using validated questionnaires, 
checklists, laboratory measurements, or vital signs (5).  
 Selection criteria Methods described in a data source as used to choose which AEs are reported 




 In this study, public sources include journal articles, conference abstracts, 
commentaries, posters, trial registrations and associated results, and medical 





In this study, non-public sources include clinical study reports and clinical study 
report-Synopses. 




A comprehensive document created by a pharmaceutical company detailing 
the design, methods, analyses, and results of a single study for submission to 
regulatory agencies. CSRs are often thousands of pages in length. Appendices 
contain tables of individual participant data, also called “patient data listings.”  





An internal company document that summarizes the information contained in 
CSRs. CSR-Synopses are much shorter than CSRs; our two CSR-Synopses were 
each 13 pages in length.  
1





Table 4-2. Process of statistical simulations  
Table 4-2 Legend: A simulation uses computer-generated data to model events to approximate real-world 
outcomes in cases where real-world data is unavailable or difficult to obtain. We have used simulations to 
model the effect of using different selection criteria on meta-analyses of randomized controlled trials 
(RCTs). We have adapted the steps for completing a simulation from previous research (245). 
Steps of performing a 
statistical simulation 
Our simulations as an example 
Clearly state the problem. How is a meta-analysis of a specific adverse event likely to be affected if 
it is based on data that have been selected for reporting, rather than all 
data that have been collected? 
Define the components which 
form the basis of the 
simulation. 
We are simulating meta-analyses, which are made up of multiple 
components in this simulation: 
Occurrence of the adverse event within the included trials, defined by 
the proportion of all participants who experienced the AE and the 
relative association of the two intervention arms (i.e., odds ratio [OR]).  
Numerical threshold for reporting, which we specified in our simulations 
based on numerical thresholds for reporting we identified in the 
literature. 
Number of included trials and participants in each meta-analysis. 
State the underlying 
assumptions and select a 
model. 
We assumed that the adverse event occurred in each trial following a 
binomial distribution with a specified probability. Our meta-analytic 
estimates of effect used the OR as a measure of association estimated 
using the Mantel-Haenszel method (246). 
Simulate a single iteration and 
record the outcomes of 
interest.  
For each iteration, we recorded the meta-analytic estimate and 95% 
confidence interval. 
Repeat step four. We performed step four 1000 times. 
Summarize the information 
and draw conclusions. 
We averaged the results of our 1000 simulated observations to get an 






Table 4-3. Fixed and varied parameters in simulations of meta-analyses of RCTs  
 
  
Description of parameter Value(s) Rationale for parameter selection 
Parameters fixed in each scenario   
  Number of participants per arm in 
each RCT 
100, 1000 A typical RCT included in a Cochrane systematic 
review has about 100 participants (231); we 
selected 1000 as a large sample size for 
comparison. 
  Number of RCTs in each meta-
analysis 
10, 50 A typical Cochrane systematic review includes 10 or 
fewer studies (231-233); we selected 50 as a large 
number of included trials for comparison.  
Parameters fixed across scenarios    
  Specified odds ratio of experiencing 
the adverse event in RCT 
3 We selected a positive association between the 
adverse event and the intervention (234-237). 
  Number of simulated meta-
analyses 
1000 Standard number of iterations for a simulation. 
  Number of arms in each RCT 2 Standard number of arms in an RCT.  
Parameters varied in each scenario    
  “True” proportion of all participants 
in RCT with AE 
1%, 2%, 3%, 
5%, 10%  
We observed these numerical thresholds for 
reporting in the eligible trials of this study. 
  Selection criterion/numerical 
threshold for proportion of all 
participants with AE required for 
reporting 
1%, 2%, 3%, 
5%, 10% 
We observed these numerical thresholds for 




Table 4-4. Comparison of adverse events reported in sources about the same trial  
Table 4-4 Legend: This table shows two types of comparisons we made. We first compared multiple 
sources about the same trial(s) that reported using the same selection criteria. We then compared data in 
the clinical study reports (CSRs), which reported all adverse events (AEs), with sources that reported 
selection criteria. A trial may appear in both sections if we identified both (1) multiple sources that 
reported using the same selection criterion and (2) a CSR for that trial. For example, we identified two 
sources that reported selection criteria as well as a CSR for Rice 2001, so Rice 2001 appears in both 
sections of the table. 
1
 Note that this section of the table does not include CSRs. CSRs are required to report summary data for 
all AEs, so they do not utilize selection criteria. 
Trial Reported selection criteria  Were sources consistent with each 
other? 
Sources about the same trial reporting the same adverse event (AE) selection criteria, when there were 
multiple sources
1 
Rice 2001 ≥5% patients (129, 132) Yes 
Sang 2013 and 
Wallace 2010 
≥3% gabapentin patients (152); ≥3% patients in 
any trial arm (150, 151) 
No: one source (152) reported one 
additional AE (150, 151) 
Calabrese 2004 ≥10% of quetiapine patients and twice as 
frequent in quetiapine patients, compared 
with placebo patients (184-186, 195)  
Yes 
McElroy 2010 ≥5% patients in any trial arm (202, 204) Yes 
Young 2008 ≥5% patients in any trial arm (216, 218) Yes 
Source(s) about the same trial reporting any AE selection criteria compared with CSR about the same 
trial 
Rice 2001 >5% patients (130) (129, 132) No: two sources (129, 132) reported 
data for two additional AEs; based 
on information in the CSR (130), we 
believe the sources reported AEs 
occurring in 5% of gabapentin-
treated patients 
Serpell 2002 ≥5% gabapentin patients (158, 160) Yes 
Calabrese 2004 ≥10% of quetiapine patients and twice as 
frequent in quetiapine patients, compared 
with placebo patients(184-186, 195); ≥10% 
patients in any trial arm (182, 194)  
Yes 
 






Table 4-5. Number of different adverse event selection criteria across sources 
about the same trial 
Table 4-5 Legend: This table only includes sources about a single trial.  





Trials with no reported selection criteria in sources about a single trial  14 0 
Trials with selection criteria reported in ≥1 source about a single trial 7 7 
  Trials with selection criteria reported in 1 source 5 3 
  Trials with selection criteria reported in >1 source 2 4 
  
 
Trials with same selection criteria reported across all sources 1 2 






Figure 4-1. Observed components of reported adverse event selection criteria  
Figure 4-1 Legend: This figure shows the selection criteria we observed in sources about gabapentin (4-2a) 
and quetiapine (4-2b). The four components of selection criteria are shown in separate columns. For 
example, the first row of boxes shows the selection criteria, “occurring in ≥1% of all participants with no 








Figure 4-2. Reported adverse events and adverse event selection criteria  
Figure 4-2 Legend. “Results” refer to any reported adverse event (AE) data (e.g., number or proportion of 
participants who experience an AE). “Selection criteria” refers to the reported methods for choosing 
which AEs to report.  
1
 12 gabapentin sources with no AEs were about a single trial; 7 gabapentin sources with no AEs were 
about multiple trials.  
2
 7 gabapentin sources with no AE results were about a single trial; 1 gabapentin source with no AE results 
was about multiple trials.  
3
 13 quetiapine sources with no AEs were about a single trial; 5 quetiapine sources with no AEs were 
about multiple trials.  
4
 8 quetiapine sources with no AE results were about a single trial; 2 quetiapine sources with no AE results 







19 (26%) sources: no 
AEs reported1 
8 (11%) sources: AEs 
reported without 
results2 
13 (18%) sources: AE 
results reported 
pooled across trials 
7 (54%) sources: AE 
selection criteria not 
reported 
6 (46%) sources: AE 
selection criteria 
reported 
34 (46%) sources: AE 
results reported by 
trial 
19 (56%) sources: AE 
selection criteria not 
reported 
9 (26%) sources: AE 
selection criteria 
reported 
6 (18%) sources: all 
AEs reported 
50 sources 
18 (36%) sources: no 
AEs reported3 
10 (20%) sources: 
AEs reported without 
results4 
5 (10%) sources: AE 
results reported 
pooled across trials 
0 (0%) sources: AE 
selection criteria 
not reported 
5 (100%) sources: 
AE selection criteria 
reported 
17 (34%) sources: AE 
results reported by 
trial 
1 (6%) source: AE 
selection criteria 
not reported 
14 (82%) sources: 
AE selection criteria 
reported 





Figure 4-3. Number of different adverse events that would be reported using 
different selection criteria 
Figure 4-3 Legend: We applied 45 different selection criteria to the data in each of the eight trials for 
which we identified clinical study reports (CSRs) and calculated the number of different adverse events 
(AEs) that met each of the selection criteria. For example, in study 945-224, 78 different AEs would be 
reported if the applied selection criterion is “≥1% of patients receiving gabapentin, with no additional 
different in magnitude.” Note that the “active” intervention group refers to either gabapentin or 
quetiapine, rather than placebo. 
To illustrate the potential variation in reported non-systematic AEs for each trial, we used a heat map to 
depict the number of different AEs that would be reported assuming less and more inclusive selection 
criteria. Numbers in the green squares  depict the non-systematic AEs that would be reported assuming 
the most inclusive selection criteria, numbers in the yellow squares depict the non-systematic AEs that 
would be reported assuming moderately inclusive selection criteria  and the numbers in red squares 
depict the non-systematic AEs that would be reported assuming the least inclusive selection criteria), for 
each trial. Squares outlined in black represent the selection criteria used in at least one source about that 
trial (e.g., a source describing Serpell 2002 reported nine different non-systematic AEs that occurred in 
≥5% of gabapentin participants with no additional criteria related to difference in frequency between 
groups). Some trials did not have any sources that described the selection criteria (e.g., 945-224). 
A No difference in frequency of AEs observed in the gabapentin/quetiapine and placebo groups; B Higher 
frequency in gabapentin/quetiapine than in placebo; C= Frequency in gabapentin/quetiapine at least 





Number of different non-systematic adverse events reported using each combination of selection 
criteria 
 Difference in frequency threshold for reporting AEs 
 
A B C 
 
A B C 
 
A B C 
 
A B C 







  Backonja 1998
1
  Rice 2001
1
 
No selection criteria (CSR) 91    198    96    108   
1% any intervention group 91 59 52 
 
76 38 26 
 
95 57 53 
 
43 32 26 
1% active intervention group 78 59 52 
 
50 38 26 
 
75 57 53 
 
34 32 26 
1% all participants 21 17 10 
 
60 36 24 
 
45 22 18 
 
29 23 17 
2% any intervention group 26 20 13 
 
34 23 16 
 
37 22 18 
 
28 22 17 
2% active intervention group 23 20 13 
 
28 23 16 
 
28 22 18 
 
24 22 17 
2% all participants 12 9 4 
 
29 20 13 
 
20 13 9 
 
14 12 9 
3% any intervention group 15 12 6 
 
24 17 14 
 
22 14 10 
 
17 13 10 
3% active intervention group 13 12 6 
 
19 17 14 
 
18 14 10 
 
15 13 10 
3% all participants 7 6 4 
 
16 11 8 
 
18 11 7 
 
10 8 7 
5% any intervention group 8 6 4 
 
8 7 6 
 
12 9 7 
 
10 8 7 
5% active intervention group 6 6 4 
 
7 7 6 
 
9 9 7 
 
8 8 7 
5% all participants 2 2 2 
 
8 7 6 
 





10% any intervention group 1 1 1 
 
4 4 4 
 
5 4 3 
 
3 3 3 
10% active intervention group 1 1 1 
 
4 4 4 
 
4 4 3 
 
3 3 3 
10% all participants 0 0 0 
 
3 3 3 
 
2 2 2 
 
2 2 2 



















No selection criteria (CSR) 122   111   316   273   
1% any intervention group 47 28 24 
 
56 35 24 
 
126 86 67 
 
123 74 57 
1% active intervention group 38 28 24 
 
47 35 24 
 
117 86 67 
 
100 74 57 
1% all participants 36 22 18 
 
32 19 11 
 
77 54 43 
 
65 41 24 
2% any intervention group 28 19 15 
 
26 16 11 
 
67 50 42 
 
58 39 22 
2% active intervention group 25 19 15 
 
24 16 11 
 
59 50 42 
 
49 39 22 
2% all participants 19 12 8 
 
20 11 6 
 
37 27 21 
 
34 26 15 
3% any intervention group 16 12 8 
 
21 13 9 
 
33 26 20 
 
30 22 14 
3% active intervention group 15 12 8 
 
18 13 9 
 
31 26 20 
 
28 22 14 
3% all participants 15 9 5 
 
12 6 2 
 
21 16 11 
 
23 15 9 
5% any intervention group 7 5 5 
 
11 6 2 
 
17 13 11 
 
21 14 9 
5% active intervention group 5 5 5 
 
9 6 2 
 
17 13 11 
 
18 14 9 
5% all participants 7 4 4 
 
9 5 2 
 
12 8 6 
 
13 9 5 
10% any intervention group 2 2 2 
 
4 2 2 
 
9 6 5 
 
8 6 5 
10% active intervention group 2 2 2 
 
2 2 2 
 
7 6 5 
 
7 6 5 
10% all participants 2 2 2 
 
3 1 1 
 
5 4 4 
 






Figure 4-4. Simulations of meta-analyses of 10 trials with 100 participants in each 
arm   
Figure 4-4 Legend: For each simulation, we ran 1000 iterations of meta-analyses of 10 trials with 100 
participants in each arm. We plotted the mean of these 1000 meta-analytic estimates with 95% 
confidence intervals for all studies (i.e., no numerical threshold for reporting) and studies that would be 
reported using each of five numerical thresholds for reporting. When the numerical threshold for 
reporting was higher than the true proportion, few studies reported AE data. Fewer studies led to a wider 
confidence interval, sometimes causing it to cross the null. Note that estimates are more precise  for 
more common  events, so the width of the confidence intervals decreased as the true proportion 
increased; this is a function of meta-analytic estimates (247). 
AE=Adverse event; *When the mean number of included studies is <1, some meta-analyses in that 
simulation would not include any data from any studies, while other meta-analyses would include data 






Figure 4-5: Simulations of meta-analyses of 50 trials with 1000 participants in each 
arm 
Figure 4-5 Legend: For each simulation, we ran 1000 iterations of meta-analyses of 50 trials with 1000 
participants in each arm. We plotted the mean of these 1000 meta-analytic estimates with 95% 
confidence intervals for all studies (i.e., no numerical threshold for reporting) and studies that would be 
reported using each of five numerical thresholds for reporting. In most cases where the numerical 
threshold for reporting was higher than the true proportion, no studies reported AE data, so no meta-
analytic estimate could be calculated. Note that estimates are more precise  for more common  events, so 
the width of the confidence intervals decreased as the true proportion increased; this is a function of 
meta-analytic estimates (247). 
AE=Adverse event; *When the mean number of included studies is <1, some meta-analyses in that 
simulation would not include any data from any studies, while other meta-analyses would include data 








Appendix 4-1. Detailed methods 
Identifying sources about eligible trials 
We searched both the International Clinical Trials Registry Platform Search Portal (ICTRP) and 
ClinicalTrials.gov for trial registrations and associated results related to gabapentin or quetiapine on 
October 10, 2014. We searched PubMed, Embase, Lilacs, CINAHL and the Cochrane Central Register of 
Controlled Trials (CENTRAL) for gabapentin and quetiapine sources, as well as PsycInfo for quetiapine; we 
completed our searches March 2, 2015 (gabapentin) and January 26, 2015 (quetiapine), without any 
language restrictions. We identified medical and statistical reviews of gabapentin as well as quetiapine 
available on the FDA website (26). We also searched certain conference proceedings and years for 
gabapentin trials (see protocol (81)). We searched online (http://psychrights.org/) for typically non-public 
sources about quetiapine for bipolar depression. We requested non-public sources in the form of internal 
company documents from the manufacturers of gabapentin and quetiapine (Pfizer and AstraZeneca, 
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Adverse events (AEs) are an important consideration when selecting a health 
intervention. Some AEs (e.g., serious AEs, “death, a life-threatening adverse event, 
inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or a congenital anomaly/birth defect” (19, 20)) can have severe medical 
consequences, and even seemingly minor AEs can result in patients discontinuing the 
intervention. It is therefore vital for healthcare stakeholders to be aware of the 
potential AEs associated with an intervention and to be able to compare the risk of AEs 
across different health interventions.  
Although regulatory agencies such as the Food and Drug Administration (FDA) 
typically have access to clinical study reports (CSRs) and individual patient data (IPD) for 
randomized controlled trials (RCTs) , not all RCTs are submitted to regulatory agencies, 
and other healthcare stakeholders often do not have access to these types of sources.  
The objective this dissertation was, to describe, in three specific aims the extent 
to which data about AEs are unavailable to healthcare stakeholders, typically with 
access to only public sources, and to assess how unreported data might impact 
systematic reviews and meta-analyses based on public sources. Here, we summarize our 
findings and describe the implications of each of the three aims, as well as draw overall 







Using RCTs examining gabapentin for neuropathic pain or quetiapine for bipolar 
depression, (a) compare the reporting of non-systematic AEs across all available sources 
(i.e., abstracts, journal articles, clinical trial registries, FDA reviews, CSRs, CSR-Synopses, 
and IPD) about RCTs and (b) assess how reporting patterns affect which evidence meta-
analyses would be based on. 
In Aim 1, we described the reporting of non-systematic AEs in 80 sources about 
21 gabapentin trials and 52 sources about 7 quetiapine trials. We identified non-public 
sources for only 6/21 gabapentin trials and 4/7 quetiapine trials. We found that nearly 
all AEs were collected using non-systematic methods. In addition, data about the 
majority of non-systematic AEs were available only in non-public sources. For example, 
341/419 (81%) and 436/471 (93%) different AEs were available only in non-public 
sources, for gabapentin and quetiapine, respectively. Thus, in most cases, healthcare 
stakeholders interested in information about non-systematic AEs would not expect to 
be able to find it in public sources, and would have to base healthcare decisions on little 
or no evidence. This is particularly problematic for serious AEs, which represent 
important risks for patients. We found that the majority of serious AEs were reported 
only in non-public sources: 56/72 (78%) in gabapentin trials and 39/46 (85%) in 




Systematic reviews and meta-analyses present the opportunity to combine 
information about rare events, because outcomes are synthesized from all relevant 
trials. Such synthesis is crucial for non-systematic AEs specifically, because RCTs are not 
usually powered to detect differences in the frequency of non-systematic AEs between 
intervention groups (72). Yet, we found that, even when non-systematic AEs were 
reported, they were not always reported completely (e.g., either the number of people 
who experienced the AE or the number of people in the analysis was not reported). This 
means that (1) patients and clinicians cannot determine the likelihood that someone will 
experience an AE on a particular intervention and (2) the data from these RCTs cannot 
be synthesized in a meta-analysis or effectively compared with RCTs on other 
interventions. Without this information, policy-makers cannot develop evidence-based 
clinical practice guidelines and patients and clinicians must make healthcare decisions 
without knowing crucial information about the relative safety of their intervention 
options. 
Aim 2 
Using RCTs examining quetiapine for bipolar depression, (a) compare the reporting of 
systematic AEs across all available sources (i.e., abstracts, journal articles, clinical trial 
registries, FDA reviews, CSRs, CSR-Synopses, and IPD) about RCTs, (b) describe the 
completeness of reporting for systematic AEs in each data sources, and (c) assess how 




When AEs are suspected of being related to an intervention, RCT investigators 
may elect to collect data about these AEs systematically. In our research, nearly all of 
the AE data we identified were collected non-systematically, rather than systematically. 
Although we planned to examine systematic AEs in both case examples (gabapentin and 
quetiapine), we did not identify any systematically collected AEs in the gabapentin for 
neuropathic pain RCTs. Therefore, the results of our second aim were based solely on 
the data from the quetiapine for bipolar depression RCTs. We identified non-public 
sources for only 4/7 quetiapine trials. 
Only one of our six pre-specified systematic AE outcome domains (mania) was 
reported in any source for all seven eligible RCTs; the remaining outcome domains were 
reported in only a subset of eligible RCTs. Failure to report systematic AEs publicly and 
completely means that healthcare decisions are based on selected subset of all 
information. Because systematic AEs are selected for collection based on their 
suspected association with the intervention, their collection and reporting is particularly 
important.  
We found that many systematic AEs reported in public sources were not fully-
defined (i.e., one or more of the elements of an outcome were not described). In 
addition, many results found in public sources were not “meta-analyzable” (i.e., 
reported in enough detail to be included in a meta-analysis). In contrast, nearly all of the 
outcomes found in non-public sources were fully-defined and their results were meta-
analyzable. For example, more than half (90/159; 57%) of results reported in public 




with nearly all (310/636; 96%) results reported in non-public sources. When data are 
incompletely reported, healthcare stakeholders are unable to synthesize data from 
multiple trials or compare the relative effect of different health interventions on 
systematic AEs.  
Although the FDA suggests that “[p]otential problems that may be suspected 
because of preclinical data or because of effects of related drugs should be targeted for 
evaluation” (13), we have been unable to identify guidance about which AEs should be 
collected systematically or what measurement tools should be used to collect these 
systematic AEs. This may lead to inconsistency in the AE outcomes collected across 
trials, which, in turn, complicates synthesizing RCTs or comparing results from RCTs of 
different interventions. To improve consistency across RCTs, we propose the 
development of core outcome sets (23, 24) specifically related to AEs.  
We propose that more AEs should be collected using systematic methods. 
Systematic methods utilize instruments, such as questionnaires or measurement tools 
(e.g., scales to measure weight), to assess information about AEs. The validity and 
reliability of these instruments can be assessed using well-established methods (222-
224). In contrast, non-systematic methods do not utilize instruments, and we are 
unaware of any methods for assessing the validity or reliability of non-systematic 
methods. Because validity and reliability are important indicators of the quality of 
research (222), using valid and reliable methods to systematically collect AEs will 





Using RCTs examining gabapentin for neuropathic pain or quetiapine for bipolar 
depression, (a) compare reported methods for selecting which non-systematic AEs to 
report both across multiple trials and across multiple sources for the same trial, (b) 
compare the non-systematic AEs reported in different sources that report using the same 
methods for selecting AEs for reporting, and (c) use simulated data to assess how using 
different “selection criteria” impacts the results of meta-analyses. 
In Aim 3, we compared the reported methods for selecting non-systematic AEs 
for inclusion in sources (“selection criteria”) about gabapentin for neuropathic pain and 
quetiapine for bipolar depression. As we found in Aim 1, non-systematic AEs were 
frequently unreported in the sources we identified. The new information related to this 
aim is that failure to report non-systematic AEs may be related to the selection criteria 
for reporting.  Often, sources that reported non-systematic AEs did not report how trial 
investigators determined which non-systematic AEs to report. When sources did 
describe how non-systematic AEs were selected for reporting, we identified a wide 
variety of reported selection criteria, both across trials and across different sources 
about the same trial(s). All of the selection criteria we identified reported selecting non-
systematic AEs based on a numerical threshold for reporting, rather than their 
importance to patients or other healthcare stakeholders.  
When multiple sources about the same trial(s) reported using the same selection 




discrepancies; different sources, including CSRs, about the same trial(s) were generally 
consistent with each other. For example, if multiple sources about the same trial(s) 
reported that they included all non-systematic AEs occurring in ≥5% of all participants, 
the sources typically reported the same AEs.  
We found no evidence that the selection criteria used in the identified trials 
were pre-specified. Using different selection criteria had a large impact on the number 
of different non-systematic AEs that would be reported. For example, there were 91 
different AEs described in CSRs for study 945-224. We found that 91/91 of these AEs 
met the selection criteria “occurring in ≥1% of any intervention group with no required 
difference in frequency.” On the other hand, 0/91 AEs met the selection criteria 
“occurring in ≥10% of all participants with no required difference in frequency.” If 
selection criteria are not pre-specified, trialists could “cherry-pick” which and how many 
non-systematic AEs to report and then identify the selection criteria that would allow 
them to report those AEs.  
Even if trialists do pre-specify selection criteria, we found using selection criteria 
based on a numerical threshold for reporting can lead to significant problems. Selecting 
AEs for reporting based on a numerical threshold for reporting can lead to meta-
analyses of publicly reported AE data incorrectly showing no evidence of effect. 
Sometimes, meta-analyses cannot be performed at all. This is particularly problematic 
because most meta-analyses of AEs are based on publicly reported data (77). Our 




Overall conclusions and future directions 
Based on the results of this dissertation, we believe there is cause for concern 
about the collection and reporting of AEs. Our evidence suggests that most AEs are 
collected non-systematically, and both non-systematic and systematic AEs, including 
serious AEs, were frequently unreported in public sources. In addition, we have shown 
that the non-systematic AEs were typically selected for publication based on the 
direction and nature of their quantitative results, which can impact the results of meta-
analyses based on these reported results. We have recommendations for trialists and 
systematic reviewers (Box 5-1), as well as recommendations for future AE research. Our 
recommendations for future research are:  
More research can be done examining design, operations and reporting for 
other interventions and indications to understand the general applicability of our 
findings to other research questions. While much of our evidence is based on two case 
studies what we have found is generally consistent with previous research (45-50, 69).   
Further research is needed about the reporting of systematic AEs, including the 
consistency of data collection of systematic AEs across trials. It is important to 
understand which AEs are collected systematically in trials and to assess how AE 
collection evolves over time as more becomes known about the potential harms of an 
intervention; improved access to typically non-public sources will allow researchers to 




More research is needed to develop core outcome sets specifically devoted to 
AEs. One of the main goals of core outcome sets is to improve consistency across trials 
to promote synthesis of trials about the same intervention and to facilitate comparison 
across different interventions. However, current core outcome sets have been 
developed with a focus on effectiveness outcomes for particular conditions (23, 24). In 
addition, the same intervention may have similar or different AEs when it is taken for 
different indications and in combination with other interventions, and this will 
complicate the development of core outcome sets. 
We believe that the research performed as part of this dissertation highlights 
both problems with existing AE research and current evidence gaps. Currently, most AEs 
are collected non-systematically, even though systematic methods can be assessed as 
valid and reliable, improving the overall quality of the research. The majority of AEs, 
both systematic and non-systematic, are unreported in public sources. This means that 
patients and other healthcare stakeholders are typically unable to access the 
information required to make evidence-based healthcare decisions. In addition, 
systematic reviews and meta-analyses, which should form the basis for clinical practice 
guidelines (243), are likely to be inaccurate or unavailable when based on only publicly 
reported data about AEs. Given the results of this dissertation and previous evidence, 
patients, clinicians, and other healthcare stakeholders are currently lacking critical 
information about the safety of health interventions.  
Open access to typically non-public sources will not solve all of the problems we 




currently unavailable data, there are also problems with the collection and analysis of 
AEs. For example, most AEs are collected non-systematically; while it is impossible to 
foresee all possible AEs, and therefore some non-systematic collection is necessary, 
known or suspected AEs should be collected systematically. In addition, there are 
hundreds of different non-systematic AEs. Grouping related non-systematic AEs for 





Box 5-1. Recommendations for trialists and systematic reviewers 
1. Incorporate both potential AEs and potential benefits into the design (as reflected 
in the protocol) and reporting of an RCT. 
2. Develop, regularly update, and use core outcome sets for AEs for interventions or 
groups of interventions (e.g., drug class). 
3. Collect data on known AEs systematically, and as evidence about AEs accumulates, 
update which AEs are collected systematically.  
4. As recommended by the FDA (13), preclinical studies, as well as trials of other 
drugs in the same class or other indications for the same drug should inform 
systematic AE collection. 
5. Pre-specify and describe collection methods for all AEs in the trial protocol and 
provide case report forms. 
6. Report collection methods for all AEs in all public sources about RCTs.  
7. Report fully-defined outcomes and complete (i.e., meta-analyzable) quantitative 
results for AEs. 
8. Make all AE data, as well as collection and analysis methods, available to the 
public; one potential mechanism for some RCTs is for the FDA to release the 
information that is submitted to them. 
9. If a particular source of information about an RCT will include data about only a 
subset of AEs, (a) do not use selection criteria based on the numerical thresholds 
for reporting, (b) describe how AEs were selected for inclusion in the source, and 
(c) direct readers to where they can find information about the unreported AEs. 
10. If, as a systematic reviewer, you encounter sources that report using quantitative 
results to select AEs for reporting, request data about all unreported AEs from the 
RCT investigator; if data is not made available, interpret your systematic review 
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